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DYSFUNCTION OF THE CREB SIGNALING PATHWAY DURING 
6-HYDROXYDOPAMINE NEUROTOXICITY 
 
 
 Elisabeth Mole Chalovich, PhD 
University of Pittsburgh, 2006
 
Disruption in important cell survival signaling pathways may represent a central mechanism in 
neurodegenerative disease processes. 6-Hydroxydopamine (6-OHDA) is an oxidative neurotoxin 
that is commonly used to injure catecholaminergic cells of the central and peripheral nervous 
systems, and has been used extensively to model Parkinson’s Disease. Although it has been 
documented that 6-OHDA elicits phosphorylation of several kinases, downstream transcriptional 
effects that influence neuronal cell death are not well defined. The cAMP response element 
(CRE) is present in the promoter sequences of several important neuronal survival factors. 
Treatment of catecholaminergic neuronal cell lines (B65 and SH-SY5Y) with 6-OHDA resulted 
in repression of basal CRE transactivation, and message levels of CRE-mediated genes such as 
brain derived neurotrophic factor and the survival factor Bcl-2 were decreased in 6-OHDA-
treated cells.  Message levels of genes lacking CRE sequences were not affected.  Interestingly, 
repression of CRE could be reversed by delayed treatment with cAMP several hours after 
initiation of 6-OHDA injury. Furthermore, this restoration of CRE-driven transcription, even up 
to 2 hours post 6-OHDA treatment, was associated with significant neuroprotection. In contrast 
to observations in other model systems, the mechanism of CRE repression did not involve 
decreased phosphorylation of its binding protein CREB.   Instead, increased phospho-CREB was 
observed in 6-hydroxydopamine-treated cells, as both total CREB and phospho-CREB were 
markedly increased in the cytoplasm after treatment.  Nuclear expression of p-CREB showed a 
  iv
different pattern, and was decreased in the nucleus of 6-hydroxydopamine-treated cells. 6-
OHDA also decreased nuclear phospho-CREB in dopaminergic neurons of primary mouse 
midbrain cultures.  Co-treatment with cAMP promoted/restored nuclear localization of phospho-
CREB in both immortalized and primary culture systems, a trend that was associated with 
protection in both B65 and SY5Y cell lines. Additionally, when human Parkinson’s/Lewy body 
brain tissue was examined, an intense clumped or granular distribution of cytoplasmic phospho-
CREB was observed in degenerating substantia nigra neurons, with little to no cytoplasmic 
staining seen in age-matched controls.  Overall, these studies suggest a common theme of 
impaired nuclear-cytoplasmic trafficking during oxidative neuronal injury processes, with 
disruption in CREB sub-cellular localization being a recurring trend.   It is interesting to note that 
cytoplasmic accumulation of upstream CREB kinases has previously been observed in both 6-
hydroxydopamine-treated cells and in degenerating Parkinson's disease neurons, further 
supporting a potential role for impaired nuclear import of phosphorylated signaling proteins in 
neuronal injury processes. These studies present important insight into oxidant-mediated 
modulation of survival signaling pathways in neuronal cells, may offer potential relevance to the 
pathogenic mechanisms underlying the progression of neurodegenerative disease. 
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1.0  INTRODUCTION 
1.1 OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS 
1.1.1 Oxidative Stress 
Oxidative stress and the damage that it can inflict on neurons has been implicated in the 
pathogenesis of many neurodegenerative diseases (Beal 1995) (Souza et al. 2000) (Tyurin et al. 
2000).  Oxidative stress – induced injury is believed to result from an imbalance between the 
production of reactive cellular oxidants and the ability of a cell’s endogenous antioxidant 
defenses to control them.  Cellular oxidants are generated normally throughout the life of a cell 
by standard metabolic processes, with a major source of reactive oxygen species (ROS) coming 
from the mitochondrial electron transport chain (Lass et al. 1997). Additional oxidants can be 
generated, however, by non-metabolic and aberrant processes within the cell through exposure to 
cytotoxic chemicals, ionizing radiation, and/or certain drugs (Galan et al. 2001).  Once 
generated, and if not neutralized, these reactive oxidants can inflict damage on proteins, DNA 
and lipids because of their ability to oxidize these important cellular components and alter them 
both structurally and functionally. Indeed, markers of oxidative stress like lipid peroxidation and 
protein nitration are found in postmortem examination of brain tissues from patients with a 
variety of neurodegenerative disorders (Sayre et al. 2001).  
 1 
In the normal, healthy cell, antioxidant defense systems exist to counteract and remove 
harmful oxidants. For example, the highly reactive superoxide (O2.-), which is generated in 
large amounts by the electron transport chain, is quickly and efficiently converted within the 
cell to the less toxic H2O2 by the superoxide dismutases, SOD1 and SOD2 (Melov et al. 1998).  
Since H2O2 itself can further react to produce the even more damaging hydroxyl radical (.OH), 
enzymes such as catalase and glutathione peroxidase also exist within cells to detoxify H2O2 by 
converting it to O2 and H2O, and therefore limit its availability to do damage the cell.  It is 
ultimately when ROS levels within a cell exceed the cell’s antioxidant capacity that the 
condition of oxidative stress occurs.  
Neurons within the CNS seem to be particularly vulnerable to oxidative stress due to a 
variety of reasons.  For example, neurons exhibit a relatively high level of metabolic activity 
along with low levels of some antioxidant enzymes like catalase and glutathione peroxidase, 
and neurons possess an inherently high amount of easily oxidized substrates, like membrane 
lipids (Reviewed in (Langley and Ratan 2004)).  Additionally, specific neuronal subtypes can 
have added sources of ROS generation.  For example, dopaminergic neurons may be further 
vulnerable to oxidative stress because dopamine itself can undergo spontaneous or enzyme-
catalyzed oxidation to generate its own source of reactive oxidants (Reviewed in (Olanow 
1990)).  Understanding how the homeostatic balance between oxidants and antioxidant 
defenses is maintained in healthy cells, as well as how this balance gets tipped in favor of 
oxidants during neuronal death processes is critical to understanding the pathogenesis of 
neurodegenerative diseases such as Parkinson’s Disease, Alzheimer’s Disease and 
Amyotrophic Lateral Sclerosis (ALS).  Given the progressive nature of these diseases, a better 
understanding of mechanisms that could disrupt antioxidant responses as well as impair a cell’s 
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adaptive responses to injury is critically important and could lead to new strategies in the 
development of therapeutic agents for neurodegenerative disorders. 
1.1.2 Parkinson’s Disease 
Parkinson’s disease (PD) is a common neurodegenerative disorder, affecting approximately 1-
2% of people over the age of 65.  It is pathologically characterized by a selective loss of 
dopaminergic (DA) neurons within the mesencephalon (specifically the substantia nigra pars 
compacta) (Lang and Lozano 1998), and a concurrent degeneration and dysfunction of the 
nigrostriatal pathway. With the progressive loss of the nigrostriatal dopaminergic neurons, there 
is a corresponding decrease of dopamine content in both the substantia nigra and striatum.  It is 
the loss of these dopamine-producing projections that is thought to account for the majority of 
physical and motor deficits seen in PD.   
Clinically, Parkinsonian symptoms are characterized and defined by the triad of 
bradykinesia (slowness and decreased amplitude of movement), tremor at rest, and muscle 
rigidity, and these symptoms as well as the underlying neuropathological hallmarks have been 
well-characterized.  However, the molecular mechanisms that lead to the progressing 
neurodegeneration still remain elusive.  While PD can affect some individuals with specific 
genetic susceptibilities, the genetic burden of actual mutations accounts for only 5-10% of the 
overall PD population. (Gandhi and Wood 2005). The majority of cases occur sporadically in the 
aging population and lack a clear etiology.   However, the remarkably consistent phenotype 
across all PD cases, whether genetic or sporadic, has lead to the conclusion that there may be 
common molecular mechanisms that underlie all cases of the disease.   
 3 
As previously stated, it is widely believed that oxidative mechanisms are a causative 
factor in the progression of Parkinson’s Disease, and evidence has long existed for the presence 
of increased oxidative stressors in PD brain (Beal 1995) (Souza et al. 2000) (Tyurin et al. 2000).  
For example, elevated levels of lipid peroxidation markers  (4-hydroxynonenal and 
malonialdehyde) as well as evidence for protein nitration have been found in the substantia nigra 
of PD patients (Andersen 2004), and reduced levels of the antioxidant glutathione can been seen 
at early stages of nigral cell loss ((Sian et al. 2004)). Additional support for a role of oxidative 
stress in PD progression has come from studies of the rarer genetic forms of the disease.  For 
example, mutations in parkin, a ubiquitin protein ligase that is mutated in some autosomal 
recessive forms of PD, have been shown to elevate levels of oxidative stress upon expression and 
make cells more sensitive to cell death processes.  (Hyun et al. 2002).   Additionally, 
overexpression of wild type DJ-1, another gene found mutated in some autosomal recessive 
forms of PD, appears to protect cells from oxidative stress induced by H2O2 (Canet-Aviles et al. 
2004).    While the exact function of DJ-1 is still unclear, evidence suggests it plays an important 
role in protecting neurons from mitochondrial-induced oxidative stress  (Gandhi, 2005).  Taken 
together, these independent lines of evidence strongly suggest that oxidative mechanisms are 
playing a role in the neuronal dysfunction and death that occurs in Parkinson’s Disease.  
Defining components of oxidant-induced death pathways in neurons is a valuable pursuit and can 
potentially lead to the development of novel therapeutic targets and/or agents for fighting this 
disease.  Since the majority of patients afflicted with PD retain otherwise normal cognitive 
function, the development of strategies to slow or halt the damage occurring in dopaminergic 
neurons could significantly improve their quality of life.  
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1.1.3 6-OHDA Model 
All commonly accepted models of Parkinson’s disease, like the actual disease itself, are thought 
to involve oxidative processes at the heart of dopaminergic injury.  Examples of such models 
include neuronal death induced by exposure to the toxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydroxypyridine (MPTP) (Cadet and Brannock 1998), the stimulant 
methamphetamine(O'Dell et al. 1991), and the dopamine analog 6-OHDA, which we have 
chosen to utilize in these experiments.  Like dopamine, 6-OHDA can oxidize to generate a wide 
spectrum of oxygen radicals (Cohen and Heikkila 1974), and targeted intrastriatal injections of 
either compound produce selective dopaminergic injury in a pattern that is almost identical to the 
loss and degeneration seen in PD brain (Przedborski et al. 1995) (Zigmond and K.A 1997) and 
(Hastings et al. 1996). Additionally, 6-OHDA has been isolated from PD patients (Andrew et al. 
1993), making this neurotoxin a potentially valuable tool to further investigate the role of 
oxidative stress in PD.  
The in vitro system utilized for studies included in this dissertation involves the use of 
two neuronal cell lines.  The first is the CNS-derived B65 cell line, which expresses tyrosine 
hydroxylase (TH), a precursor enzyme involved in dopamine production, and has electrically 
excitable membranes that can generate action potentials (Schubert et al. 1974).  The second is the 
human dopaminergic neuroblastoma SH-SY5Y cell line, which expresses dopamine hydroxylase 
and the dopamine transporter (DAT) (Decker et al. 1993). Cultures of B65 and/or SH-SY5Y 
cells offer a homogeneous population of neuronal cells to study signaling mechanisms that may 
be occurring in response to oxidative stress in dopaminergic neurons.  
 Of course, there are limitations to this model.  For example, a transformed cell line 
cannot be considered completely analogous to mature neurons, and typical neuronal responses 
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may be lacking in these cells. Therefore, when possible, results obtained were confirmed using 
primary neuronal cultures obtained from mouse midbrain.  Additionally,   since we are in the 
unique position to have access to banked human Parkinson’s disease tissue, we were able to use 
this tissue to further confirm the validity of our observed results as they relate to the human 
disease itself.   
1.2 THE ERK-RSK-CREB NEURONAL SURVIVAL SIGNALING PATHWAY. 
1.2.1 ERK Signaling Pathway 
Although increasing evidence points to a role for the process of oxidative stress in neuronal 
degeneration, to date little is known about the molecular players responsible for controlling this 
avenue of cellular fate.  One of the most notable and commonly activated signal transduction 
pathways within a cell is the Mitogen Activated Protein Kinase (MAP Kinase) signaling cascade.  
MAP kinases are serine/threonine kinases that play important roles in transducing extracellular 
signals from the membrane to the nucleus.  They are activated by a wide variety of stimuli, 
ranging from neurosupportive signals like neurotrophic factors, to cell stressors like reactive 
oxygen species (Reviewed in (Chang and Karin 2001), (Grewal et al. 1999)and (English et al. 
1999).   The ERK branch of the MAPK pathway includes ERK1 and ERK2 (also known as p44 
and p42 MAP kinases), which are activated upon phosphorylation of specific tyrosine and 
threonine residues by the MAPK kinase, MEK.  MEK is in turn activated via phopsphorylation 
by the MAPK kinase kinase, Raf, which itself can be activated by various mechanisms.  
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Historically, ERK has been associated with favorable cellular functions, like 
proliferation, differentiation and survival (Xia et al. 1995) (Segal and Greenberg 1996) and 
(Ballif and Blenis 2001), and proper ERK function is essential to the normal development and 
functional plasticity of the CNS (reviewed in (Chu et al. 2004)). Recently however, in our 
laboratory and in others, the ERK branch of the MAPK family has also been implicated in the 
death of neuronal cells  (see references below). Interestingly, the majority of the studies 
described to date, using models of neurodegeneration, cerebral ischemia and brain trauma, have 
involved death induced by oxidative mechanisms, suggesting that ERK may be specifically 
involved in this mode of neuronal damage. For example, in two laboratories that utilized a 
glutamate-induced model of oxidative stress, data show that not only does glutamate activate 
ERK, but inhibition of the upstream ERK activator, MEK, leads to protection from the oxidative 
toxicity (Stanciu et al. 2000) and (Satoh et al. 2000).  This result was evident in a hippocampal 
cell line (HT22 cells) and primary neuronal cultures.  Additionally, it has also been shown that 
inhibition of ERK phosphorylation (again via MEK inhibition) can protect neurons from damage 
induced by focal cerebral ischemia in rodents (Alessandrini et al. 1999), as there is increased 
neuronal survival when ERK activation was blocked.  Data from our own laboratory show that in 
response to the oxidative neurotoxin 6-OHDA, neuronal cells exhibit an abnormal, sustained 
pattern of ERK phosphorylation, which could be inhibited by MAP kinase kinase (MEK) 
inhibitors (Kulich and Chu 2001).  Since the inhibition of abnormal ERK activation also offered 
significant protection from the cytotoxic effects of 6-OHDA, these data suggest also that ERK 
phosphorylation directly contributes to the dopaminergic neuronal death mechanisms that are 
involved in oxidant-induced neuronal cell death (Kulich and Chu 2001). Given the vastly 
different and contradictory functions of ERK within the CNS and in various models of death, a 
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further and more detailed examination of the molecular events that occur downstream of the 
sustained ERK activation in 6-hydroxydopamine-induced neurotoxicity is essential.   
Once activated, ERK can phosphorylate target proteins within the cytoplasm, or can 
translocate to the nucleus where it can modulate the activity of various transcription factors.  One 
well-known cytoplasmic target of ERK is the serine/threonine kinase, p90rsk. When RSK 
becomes active, it can similarly target proteins in the cytoplasm, or move to the nucleus (usually 
co-translocating with ERK) to affect nuclear targets (reviewed in (Grewal et al. 1999)).  
Members of the RSK family, consisting of RSK1, 2 and 3, are thought to be activated in 
response to mitogenic stimuli, but the regulation of their activation is complex and not well 
understood (Alessandrini et al. 1999).  Susequent work utilized novel RSK constructs to examine 
the hypothesis that RSK was a downstream effector of MAP kinase–induced cell survival 
(Shimamura et al. 2000).  These authors found that a kinase-dead mutant of RSK1 inhibited the 
MEK-dependent survival signal in HEK cells, while a constitutively active RSK1 restored the 
survival effect observed with activation of MEK.  This confirmed that RSK does indeed play a 
downstream role in this important survival pathway. Additionally, a separate study by Bonni et al 
(1999) (Bonni et al. 1999) used neuronal primary cultures and showed similar results with RSK2, 
and went a bit further to suggest that one of the mechanisms by which the MAPK-RSK pathway 
promotes cell survival is via phosphorylation of RSK’s downstream nuclear target, CREB.    
1.2.2 CREB. 
cAMP-response element binding protein, CREB,  belongs to a family of transcription factors that 
have been implicated in many important neuronal functions (Walton and Dragunow 2000), 
(Finkbeiner 2000), and (Shimamura et al. 2000).  For example, CREB-dependent gene 
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expression has been reported to play a role in such diverse processes as cell survival, plasticity, 
growth and development, and most recently, cell death.   In neurons and other cells, CREB and 
its family members function as effector molecules that bring about changes within a cell in 
response to a wide range of signals. Diverse extracellular stimuli such as growth factors, 
hormones, membrane depolarization and Ca2+ influx can all cause activation of CREB, and the 
multiple different signaling cascades all converge to phosphorylate a critical CREB residue- 
Serine 133 (Reviewed in (Mayr and Montminy 2001)). Since CREB is phosphorylated in 
response to such diverse signals, as well as through such diverse intracellular pathways (Figure 
1), just how specificity is achieved has been the subject of much debate.  Unfortunately, these 
complex mechanisms are still not totally clear.   
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Figure 1.   CREB Activation Pathways. 
CREB can be activated (phosphorylated) by a variery of signaling pathways.    The most 
common and best elucidated is the cAMP-PKA pathway.  Extraceullular signals  (ex: 
Hormones and neurotransmitters) activate heterotrimeric G-proteins, that directly 
stimulate adenyl cyclase, which can then catalyze the production of cAMP.  cAMP then 
leads to the activation of PKA, which dissociates into active catalytic subunits which can 
diffuse into the nucleus and phosphorylate CREB.   Additionally, growth factors can 
stimulate their respective receptors, which can lead to stimulation of Raf and the 
downstream kinases RAS, MEK and ERK.  Activated ERK can them stimulate RSK to 
translocate to the nucleus to phosphorylate CREB.  Furthermore, intracellular Ca++ can 
stimulate the PKA pathway (through calmodulin) or activate members of the 
Calmodulin-dependent kinase family (CcamK) which can phosphorylate CREB directly. 
Once activated, pCREB controls the transcription of various important genes. 
 
As its name suggests, CREB is activated in response cAMP, and this mechanism of 
activation is well-characterized.  (CREB is also activated by the MAP Kinase pathway (via 
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RSK), by PKC, and Ca2+ and calmodulin dependent kinase (CaMKIV), see Figure 1).  cAMP 
accumulates in the cytoplasm in response to stimulation of membrane (G)-protein coupled 
receptors and stimulates the dissociation of the protein kinase A (PKA) heterotetramer, which 
consists of a pair of regulatory (R) and a pair of catalytic (C) subunits.  Once liberated, the 
catalytic subunits are free to enter the nucleus by passive diffusion where they phosphorylate 
CREB on its Ser-133 residue, and gene expression can then be induced.  Phosphorylation on this 
serine is critical to transcriptional activation, as mutagenesis studies (substitution of Ser-133 with 
Ala) show that Ser-133 mutation causes a disruption in stimulus-induced CREB activity. 
(Gonzalez and Montminy 1989).   Furthermore, gain-of-function mutations that mimic Ser-133 
phosphorylation confer on CREB the ability to activate CRE reporter gene transcription in the 
absence of stimulation (Du et al. 2000). 
1.2.2.1 Kinetics of CREB activation.   
Once cAMP levels are increased in the cytoplasm, stimulating the dissociation of PKA, the 
released catalytic subunits are free to diffuse about the cell and phosphorylate target proteins.  As 
mentioned, the subunits can also passively diffuse into the nucleus, where they can activate their 
nuclear substrate, CREB.  Transcription of CREB-mediated genes usually peaks at about 15-30 
minutes post-stimulus, which corresponds well with the time needed for PKA’s catalytic 
subunits to become maximal in the nucleus  (Hagiwara et al. 1993).  Most cAMP-regulated 
genes studied to date have been found to be induced transiently (Hagiwara et al. 1992).  Even in 
the presence of constant stimulation, CREB activity typically attenuates and declines to baseline 
over the next 2-4 hours with dephosphorylation of CREB Ser-133 paralleling the decline in 
transcriptional activity (Hagiwara et al. 1992).  Dephosphorylation is achieved by two okadaic 
acid-sensitive, serine/threonine phosphatases, protein phosphatase-1 (PP-1) and protein 
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phosphotase PP-2A (Hagiwara et al. 1992) and (Wadzinski et al. 1993).  As this is the typical 
pattern of CREB activation, it has become clear that this is certainly not the only pattern.  Even 
within specific brain regions, responses to the same stimulus can vary neuron to neuron.  For 
example, in some subtypes of striatal neurons, stimulation with dopamine (which activates 
cAMP) causes CREB phosphorylation that is sustained for more than 30 minutes.  Yet in other 
striatal neuron subtypes, cAMP signals induce a much shorter CREB activation response, such 
that CREB is dephosphorylated within 15 minutes of the initial stimulus (Liu and Graybiel 
1996). Interestingly, these subtle differences result in the differential expression of downstream 
genes (Liu and Graybiel 1996). Clearly, mechanisms of controlling CREB activation are intricate 
and complex, and consist of many levels of checks and balances. 
1.2.2.2 Binding of CREB to CRE. 
One point of control by which specificity in CREB signaling can be achieved within a cell exists 
at the DNA binding level.  Typically, CREB binds as a dimer to a conserved cAMP Response 
Element (CRE), an 8 base pair sequence of TGACGTCA (Comb et al. 1986).  These CRE sites 
have been found to exist in more than 100 gene promoters, with about half containing this full 
CRE palindrome, and half containing the half site, CGTCA (Mayr and Montminy 2001).   To 
date, whether CREB binding to CRE occurs before or after phosphorylation remains 
controversial, as evidence seems to exist for both views. For example, it has also been shown 
that CREB dimerization is strongly promoted in the presence of CRE DNA, and this 
dimerization occurs independent of phospohrylation status  (Metallo and Schepartz 1997), and 
(Wu et al. 1998).   Additionally, chromatin does not seem to impose a physical barrier on CREB 
binding to CRE (Mayall et al. 1997).   However, for some gene promoters, the CRE site seems to 
be constitutively bound, while in others, cAMP will actively stimulate CREB to bind to and 
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occupy CRE (reviewed in (Mayr and Montminy 2001)).  It has been suggested that occupancy of 
CRE by CREB can be regulated by DNA methylation, but studies indicate that additional, 
unknown levels of regulation also likely contribute.   It is reasonable that different levels of CRE 
occupancy can account for some measure of the cells ability to mediate specificity in CREB 
signaling. 
1.2.2.3 Regulation of CREB transcriptional activity.    
Once CREB is bound to CRE and phosphorylated, whether or not gene expression is induced is 
further regulated, and varies greatly depending on both the stimulus as well as the gene 
promoter.  For example, there are documented differences in CREB activity in cells treated with 
cAMP versus stress or mitogen signals.   When looking at the promoter level, a single CRE site 
can be sufficient for gene activation through CREB after treatment with cAMP  (Matthews et al. 
1994).  However, in response to growth factors, phosphorylation of CREB may not be enough, 
as additional promoter-bound factors are needed in order to achieve CREB-mediated gene 
expression (Bonni et al. 1999).   Additionally, to add another level of complexity, in other cell 
types (Jurkat cells), active CREB phosphorylation can be achieved without any subsequent 
activation of a CRE reporter gene (Brindle et al. 1995).  Thus, various stimuli are able to 
discriminate between gene targets, and/or gene promoters are able to discriminate between the 
different signals.  How is a cell capable of mediating specificity in CREB signaling, allowing a 
gene promoter to respond to one signal but not another, despite similar levels of 
phosphorylation?  The answer likely reflects not only different levels of occupancy of CREB 
over CRE, but more importantly, the ability of a cell to recruit different cofactors to the 
transcriptional apparatus.   
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1.2.2.4 CREB localization 
CREB is a ubiquitously and constitutively expressed transcription factor that is generally 
assumed to be targeted to the nucleus immediately after synthesis in the cytoplasm.  Indeed, a 
nuclear localization signal (NLS) has been mapped to the CREB gene (Waeber and Habener 
1991). This widely held view, however, has been questioned on occasion, as multiple reports 
describe the presence of CREB immunoreactivity outside of the nuclear envelope.  For example, 
CREB has been reported in developing dendrites of cultured neurons (Crino et al. 1998),  in the 
postsynaptic densities of rat brain ((Suzuki et al. 1998)), as well as in cytosolic fractions from 
mouse hippocampus (Azuma et al. 1999).  Additionally, CREB immunoreactivity as well as 
CRE binding activity has been described in mitochondrial fractions from rat brain  (Cammarota 
et al. 1999). However, despite these reports, which all examined neuronal systems, the idea that 
CREB could function or even exist outside of nuclei in neurons is still widely ignored.  In a more 
recent report, (Kuramoto et al. 2005) found that immunoreactive CREB was detectable in both 
nuclear and cytosolic fractions of individual mouse brain structures.  Interestingly, suppression 
of new protein synthesis by cycloheximide in vivo resulted in a significant decrease in nuclear 
CREB and a corresponding increase in cytoplasmic CREB levels in mouse hippocampus.  This 
effect was restricted to specific brain regions, raising the possibility that regulation of nuclear 
import/export of CREB may vary from brain region to brain region through a previously 
unidentified mechanism other than an NLS.  This additional mechanism could act as a 
supplementary level of control of a cell’s responsiveness to the variety of extracellular signals 
that CREB must discriminate between.  More specifically, this mechanism may represent a cell’s 
response to harmful or toxic stimuli.   
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1.2.3 CREB Binding Protein. 
CBP (CREB-binding Protein) was first identified when a cDNA expression library was screened 
with 32P-labeled CREB to search for factors that associate with CREB and therefore may 
contribute to transcriptional control (Chrivia et al. 1993).  CBP is a 265 kDa nuclear protein that 
associates with phosphorylated CREB, and acts as a critical transcriptional co-activator.   This 
idea is supported by multiple lines of evidence.  For example, anti-CBP neutralizing antibodies 
cause inhibition of cAMP-mediated expression of a CRE reporter vector (Arias et al. 1994), and 
the same amino acids that are most critical for CREB transcription are also those that are 
required for interaction of CREB with CBP.   It is likely that CBP acts as a transcriptional 
adaptor – serving as a bridge to allow phosphorylated CREB to recruit and interact with the RNA 
polymerase complex at the TATA box.  Indeed, both CBP and RNA polymerase co-
immunoprecipitate with Ser-133 pCREB (Kee et al. 1996). Since RNA helicase was also found 
to immunoprecipitate, and  co-expression of CBP with this RNA helicase increased CREB’s 
ability to activate transcription (Nakajima et al. 1997), it is likely that both are involved in 
linking CREB to the transcriptional machinery.   
After CBP is recruited to the gene promoter, it is proposed to mediate activation of target 
genes not only through its association with RNA polymerase, but also through its intrinsic 
histone acetyltransferase activity (Ogryzko et al. 1996; Yang et al. 1996).  By encouraging the 
acetylation of amino acids on histones, chromatin structure is altered in such a way as to make it 
more accessible to the entire transcriptional apparatus.  As would be expected, CBP function is 
critical in the wide range of CREB-mediated cellular functions, and disruption in CBP function 
can have devastating effects on normal development.  For example, mutations in humans causing 
loss of function of one CBP allele results in the Rubinstein-Taybi syndrome (reviewed in 
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(Rouaux et al. 2004)), which is characterized by physical abnormalities as well as mental 
retardation.   Additionally, disruptions in CBP function have also been implicated in the 
pathology of the neurodegenerative disorder, Huntington’s Disease, an effect that will be 
discussed in greater detail below. 
1.3 DISRUPTIONS IN ERK-RSK-CREB SIGNALING IN NEURONAL DEATH. 
1.3.1 CREB is important in neuronal survival.  
While CREB function has been implicated in development, learning and memory, and plasticity, 
arguably one of the most important roles of CREB is in the promotion and regulation of neuronal 
survival.   The first reports to document CREB-dependent mechanisms of neuronal survival 
showed that neurotrophic factors could inhibit cell death processes, in large part by working 
through CREB (Bonni et al. 1999; Riccio et al. 1999).  For example, Bonni et al (1999) 
investigated the role of MAPK in the BDNF-induced survival of cerebellar neurons, and 
determined that activation of transcription factor CREB was necessary for this survival.  
Interestingly, they also discovered that if they inhibited the activation of CREB, (by using a 
dominant-interfering mutant or one in which the crucial ser 133 phosphorylation site was 
mutated) they could trigger apoptosis in these cells.  A separate study using similar mutant 
constructs, again showed that genetically inactive CREB could cause death of cerebellar granular 
neurons, while an active CREB mutant reduced cell death in response to oxidative stress (See 
and Loeffler 2001).   Additionally, See and Loeffler (2001) showed that exposure to H2O2 
blocked CREB phosphorylation, and if CREB phosphorylation is restored, neurons can be 
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protected from oxidant-induced cell death.  Taken together, these results indicate that proper and 
intact CREB function is critical to neuronal survival, not only during development, but also 
during cell responses to injury. 
CREB may control neuronal survival, in part, by controlling transcription of 
neuroprotective genes.  For example, the promoter regions for both Brain Derived Neurotrophic 
Factor (BDNF) and the anti-apoptotic protein, Bcl2, each contain CRE sites (Mayr and 
Montminy 2001) and both of these gene products have been shown to play an important role in 
neuronal survival.  Additionally, transgenic mice that overexpress Bcl2 are protected from 
naturally occuring neuronal loss as well as experimentally-induced ischemia  (Martinou et al. 
1994).  Additionally, treatment of neuronal cells with oxidants causes a decrease in Bcl2 at both 
the protein and mRNA levels, as well as a decrease in the CRE-mediated Bcl2 promoter activity 
(Pugazhenthi et al. 2003).   BDNF is also known to affect neuronal survival, as this neurotrophic 
factor can protect nigrostriatal dopaminergic neurons from neurotoxins in rodent and monkey 
models of Parkinson's disease (PD)  (Sun et al. 2005).  Interestingly, BDNF has also been shown 
to be able to stimulate proliferation of neuronal precursors and the possible generation of new 
dopaminergic neurons in the striatum and substantia nigra in the unilateral 6-OHDA lesion rat 
model of Parkinson’s disease (Mohapel et al. 2005). Taken together, these results confirm that 
CREB, together with its downstream gene products, play an important role in the regulation of 
neuronal survival throughout the life of a neuron.  Activation during development, as well as 
during times of stress is critical for determining neuronal fate, opening up the possibility that 
disruption of this important signaling pathway would have detrimental consequences. 
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1.3.2 CREB is disrupted in neuronal degeneration and death.  
Many lines of evidence now exist for the role of CREB function in neuronal survival, and it is 
likely that this important transcription factor plays a key part in the adaptive response of neurons 
to insult and/or injury.  Accordingly, CREB has been shown to be activated in response to 
stressful and toxic stimuli. It is possible that the activation of CREB-dependent signaling in 
response to harmful stimuli may represent a defense mechanism in neuronal cells.  Indeed, 
studies implicate CREB activation in the selective vulnerability of hippocampal neurons in 
response to injury, and this activation correlates well with neuronal survival.  For example, after 
hypoxic injury, there is an increase in activated CREB within apoptosis-resistant neurons of the 
dentate granule-cell layer, whereas both CREB and pCREB are markedly decreased in the dying 
CA1 pyramidal cells. (Reviewed in (Walton and Dragunow 2000)).  This activation of CREB 
within the dentate region and corresponding loss in the CA1 neurons (which precedes the onset 
of cell death) suggest that neuronal survival is intimately linked to the ability of a cell to activate 
CREB.  This hypothesis is further substantiated by later work showing that injection of CRE 
decoy oligos during toxic stimuli is associated with increased cell death  (Mabuchi et al. 2001), 
indicating that neuroprotective responses require CREB-dependent gene expression. 
In agreement with this idea, several human conditions exist where CREB function is 
disrupted.  For example, in Coffin-Lowrey syndrome, the gene that encodes RSK-2 (an 
important CREB kinase described earlier) is mutated (Abidi et al. 1999), resulting in severe 
physical and mental abnormalities in humans.  And as previously described, a heterozygous 
mutation in CBP results in Rubinstein-Taybi syndrome, which is also characterized by mental 
and skeletal deficits. Additionally, CREB dysfunction is thought to play a role in the 
neurodegenerative disorder Huntington’s Disease.   
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Huntington’s Disease is a member of the CAG repeat family of neurodegenerative 
diseases and is characterized by the presence of an expanded polyglutamine (polyQ) repeat in the 
huntingtin (htt) protein. The important CREB co-activator, CBP, has been implicated as being 
central to the pathology of this disease, as nuclear inclusions that contain mutant huntingtin 
recruit and sequester CBP, presumably disrupting its ability to influence CREB-mediated gene 
transcription (Nucifora et al. 2001). Overexpression of CBP can protect cells from toxicity 
associated with expression of mutant huntingtin, providing further evidence that loss of CBP 
function contributes to neuronal death.  Additionally, in more recent study, Shimohata et al 
(2005) (Shimohata et al. 2005) showed that expanded polyglutamate stretches can strongly 
suppress CREB phosphorylation as well as induction of CRE-mediated transcriptional activation.  
Further, the suppression of CREB dependent transcription was reversibly rescued by increasing 
concentrations of cAMP, which also protected cells from the neurotoxic effects of expanded 
polyglutamine.  Thus, the ability of CREB to become transcriptionally active, whether through 
phosphorylation, RSK activation, CBP association, or cAMP, appears to be required for neuronal 
survival in many circumstances, and may have particular relevance to human diseases.  
1.4   SUMMARY 
CREB is a nuclear cellular transcription factor that is critical to many important cellular 
functions. Since CREB is activated in response to various different signals, and controls the 
expression of more than 100 different genes, just how CREB signaling is differentially regulated 
within the cell has been the subject of much debate.  To date, research has shown that CREB 
signaling can be modulated at many levels.  For example, the mechanisms of CREB 
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phosphorylation, CREB occupancy of CRE, and the binding of CREB cofactors at the 
transcriptional apparatus have all been shown to play a role in achieving specificity, and it is 
likely that additional measures of regulation also exist, but are undetermined as of yet. It is not 
difficult to surmise that disruption at the level of any of these control mechanisms could impair a 
cell’s ability to respond appropriately to cell signals, and could have detrimental effects on cell 
function.   
One of CREB’s most important roles within a neuron is the control of cell survival.  
Indeed, proper CREB function is needed for neuronal survival not only during development, but 
also during neuronal response to harmful or toxic stimuli.  One would predict that the inability of 
a cell to activate proper adaptive CREB-mediated survival responses would have devastating 
effects.  In this study, we examined adaptive responses to oxidative stress in neurons, and in 
particular, examined the impact of the neurotoxin 6-hydroxydopamine on CREB-mediated 
survival signaling.  Defining the mechanism(s) behind oxidant-induced cell death can potentially 
lead to the development of novel therapeutic strategies for fighting neurodegenerative diseases. 
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2.0  RATIONALE AND HYPOTHESIS 
Oxidative stress has been implicated in a variety of pathological processes, ranging from 
ischemic cell death and aging to neoplastic transformation and autoimmune disorders.  In 
particular, oxidative mechanisms have been strongly linked to the pathogenesis of age-related 
neurodegenerative diseases, including Parkinson’s Disease, Alzheimer’s Disease, and 
Huntington’s Disease (Barnham et al. 2004). The central nervous system may be particularly 
susceptible to oxidants due to neurons’ high levels of metabolic activity and relatively low levels 
of endogenous antioxidants.  Indeed, markers of oxidative stress, including lipid peroxidation 
and protein nitration, are increased in affected brain areas in Alzheimer’s, Parkinson’s and 
Amyotrophic Lateral Sclerosis (Beal 1995) (Souza et al. 2000) (Tyurin et al. 2000)  and 
antioxidants have been shown to provide protection in their respective animal and culture models 
(Wu et al. 2003) (Cassarino et al. 1997) (Callio et al. 2005) (Wu et al. 2003).  While the 
mechanism(s) by which reactive oxygen species influence cell survival-death decisions still 
remain incompletely defined (Ellerby and Bredesen 2000) (Barlow et al. 2005), there is little 
doubt that oxidative processes play an important role in the propagation of neuronal injury.  
Since the neurons that degenerate in these diseases show a regional vulnerability that is specific 
to each disorder, oxidative processes may be a factor that links the unique death pathways in 
neurodegenerative diseases. Given the progressive nature of neurodegenerative diseases, a better 
 21 
understanding of mechanisms that could impair adaptive responses to injury is particularly 
important. 
6-Hydroxydopamine (6-OHDA) is an oxidative neurotoxin that has been used extensively 
to lesion the nigrostriatal system that degenerates in Parkinson's and related diseases.  In such 
studies, targeted intrastriatal injections of 6-OHDA in mice and rats result in a pattern of 
selective dopaminergic injury that is almost identical to neuronal loss and degeneration seen in 
PD brain (Przedborski et al. 1995) (Zigmond and K.A 1997). Neuronal injury in response to 6-
OHDA may result from its ability to spontaneously autoxidize, resulting in the generation of a 
wide spectrum of reactive oxygen species (ROS) including hydrogen peroxide, superoxide and 
hydroxyl radical(Cohen and Heikkila 1974).  While both in vivo and in vitro studies implicate 
this intracellular oxidative stress in 6-OHDA neurotoxicity (Callio et al. 2005) (Asanuma et al. 
1998) the exact mechanism of neuronal cell death is still unclear.  It has recently been shown that 
6-OHDA treatment elicits activation of several kinases including extracellular signal regulated 
protein kinases (ERK) (Kulich and Chu 2001) (Horbinski and Chu 2005), however the 
downstream transcriptional mechanisms by which 6-OHDA modulates cell survival-death 
decisions still remain incompletely defined.  
CREB (cyclicAMP Response Element Binding protein) is a transcription factor that plays 
an important role in neuronal survival, in part by controlling the transcription of neuroprotective 
genes such as Brain Derived Neurotrophic factor (BDNF) and the pro-survival protein Bcl-2 
(Finkbeiner 2000) (Mayr and Montminy 2001). Studies show that cAMP, a potent activator of 
CREB, acts as a trophic or protective signal for several populations of catecholaminergic neurons 
(Reviewed in (Goldberg and Barres 2000)), and can enhance the protective effects of 
noradrenaline (Troadec et al. 2002)and glial cell line derived neurotrophic factor (Engele and 
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Franke 1996).  Interestingly, related studies show that oxidative stressors can disrupt CREB 
function, for example by interfering with CREB phosphorylation and/or by reducing CRE 
binding activity (Ito et al. 1999) (See and Loeffler 2001). An additional study examined the 
impact of oxidative stressors on the downstream CRE-mediated survival gene Bcl2 (Pugazhenthi 
et al. 2003) and reported that oxidative stress causes a down-regulation of the Bcl2 promoter, 
resulting in a decrease in Bcl2 protein as well as mRNA levels.  Taken together, these results 
suggest that a loss of CREB signaling could contribute to oxidant – induced neuronal 
dysfunction, and may be particularly important under conditions of oxidative stress.  
Specifically, since CREB can be activated by neurons in response to insult, and this CREB 
activation is typically associated with increased survival, any interruption in this adaptive 
survival response may hinder a neuron’s ability to protect itself. 
The potential role of the CREB pathway in neuronal cell responses to 6-
hydroxydopamine was investigated in this study.  Since previous data has implicated CREB 
functioning in neuronal death processes, we questioned whether disruption of CREB signaling 
contributes to the cell death process in Parkinsonian models, to better clarify the mechanisms 
involved in 6-OHDA-mediated toxicity.  Since previous data in our laboratory demonstrated 
alterations in two upstream CREB kinases, ERK and RSK, with both showing abnormal 
cytoplasmic accumulation in 6-OHDA-treated cells and degenerating Parkinson’s disease 
neurons (Zhu et al. 2002), we sought to examine downstream effects on transcription that may 
influence neuronal death.  We hypothesized that CREB signaling will be altered in response to 
6-OHDA, with downstream CREB-mediated transcription disrupted, resulting in a decrease in 
expression of important survival gene products.  A better understanding of neurodegenerative 
mechanisms, with elucidation of a transcriptional mechanism for oxidative stress-induced 
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neurotoxicity would offer important insights into the pathogenic mechanisms underlying the 
progression of neurodegenerative diseases. 
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3.0  MATERIALS AND METHODS 
3.1 CELLS AND TISSUES 
3.1.1 Cell Culture 
B65 cells (ECACC 85042305) were the gift of Dr. David Schubert of the Salk Institute, La Jolla, 
CA (Schubert et al. 1974). SH-SY5Y cells were purchased from ATCC (Manassas, VA). Both 
cell lines were maintained in Dulbecco’s modified Eagle’s Medium (DMEM), supplemented 
with 10% heat-inactivated fetal calf serum, 2mM L-Glutamine and 10mM HEPES. Low-serum 
media consisted of DMEM supplemented with 0.5% heat-inactivated fetal calf serum, 2mM L-
glutamine and 10mM HEPES. Cell culture reagents were purchased from Biowhittaker 
(Walkerville, MD) unless otherwise indicated.  In a typical experiment, B65 and SH-SY5Y cells 
were plated at a density of 3x105 cells/well for 6-well plates, 1x104 cells/well in 96 well plates, 
or 1x106 cells/well in 100 mm dishes.  For all experiments, cells were cultured in a humidified 
incubator with 5% CO2 at 37oC. 
3.1.2 Primary midbrain cultures 
Primary midbrain neuronal cultures were derived from 15-day C57BL/6 mouse embryos as 
previously described (Chu et al. 2005). Briefly, the striatum and ventral midbrain were dissected 
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from the embryos (Hilltop Laboratory Animals, Inc., Scottdale, PA, USA), and incubated with 
100 units papain (Worthington Biochem. Corp. Lakewood, NJ, USA) in Hank's Balanced salt 
solution for 30 min at 37°C. Cells were then mechanically dissociated using a flame-polished 
Pasteur pipette in Dulbecco's modified Eagle's medium/Ham's F12 1 : 1 (v/v; GIBCO/Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine seum (Cambrex Biological Science, 
Walkersville, MD, USA), 5 mg/L insulin (Invitro Life Technologies) and 30 mM D-glucose 
(Sigma, St Louis, MO, USA). Cells were collected by centrifugation at 200 g for 5 min, 
resuspended in culture medium and plated in poly-L-lysine coated 16-well chamber slides (Nunc 
Laboratory-Tek, Fisher Scientific, Agawam, MA, USA) at a density of 2 × 105 cells/cm2. or 
seeded into 12 or 96 well plates.  Cultures were maintained at 37°C in 5% CO2. After 3 days, 
fresh medium containing 2 µM cytosine arabinoside was applied for 72 h to inhibit the 
proliferation of glia. Cultures were treated at between 7-9 days in vitro with 50 μM of 6-OHDA, 
a dose selected based on published death curves (Guo et al. 2001), and/or 100uM db-CAMP 
(Kim et al. 2005) as indicated in figure legends. After 3 hours, the chamber slides or cell culture 
plates were washed in PBS (20mM potassium phosphate, 150mM potassium chloride), fixed in 
3% paraformaldehyde for 15 minutes, and then processed for immunofluorescence as described 
in detail in the Methods below. 
3.1.3 Human Tissues 
Paraffin-embedded midbrain sections were obtained from the Joseph and Kathleen Price Bryan 
Brain Bank and the University of Pittsburgh Brain Bank.  All banked patients have undergone 
extensive standardized pre-mortem neurological and post-mortem neuropathological 
assessments.  Available PD, DLB, and incidental Lewy Body disease cases were requested, 
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along with a set of normal control cases matched for age and postmortem intervals.  
Additionally, sections of breast cancer tissue were requested to serve as a positive control for 
CREB antibodies.  The study design was approved by the University of Pittsburgh Institutional 
Review Board. 
3.2 TRANSCRIPTION, VIABILITY AND CELL DEATH ASSAYS 
3.2.1 Transcription assays 
The CRE reporter vector from the Mercury Pathway Profiling System (Clontech, PaloAlto, CA) 
was cloned and purified using endotoxin-free Maxi-Prep kits (Qiagen, Valencia, CA).  The 
empty, backbone vector (pTAL) was used as a control.  Both pTAL and pCRE contain a TATA-
like promoter region from the Herpes simplex virus thymidine kinase (HSV-TK) promoter (to 
provide optimal induction of reporter, while giving low background), and the firefly luciferase 
coding sequence (from Photinus pyralis), which is followed by the SV40 late polyadenylation 
signal to ensure proper, efficient processing of the luciferase transcript in eurkaryotic cells (See 
Figure 2).  Additionally, there is a transcription blocker, which is composed of adjacent 
polyadenylation and transcription pause sites for reducing background transcription, as well as 
an ampicillin resistance gene, to allow for propagation and selection in E.coli.  The pCRE vector 
contains the above components as well as three copies of the CRE-binding sequence fused to the 
TATA-like promoter region of the HSV-TK promoter.  After transcription factors bind CRE, 
transcription is induced and the reporter gene is activated and ultimately translated into 
functional enzyme.   
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Figure 2.   pTAL and pCRE plasmid maps. 
The structure of both pCRE and control pTAL plasmids are shown.   Note that vectors 
are identical except for the tandom repeats of CRE found on the pCRE plasmid.  Both 
plasmids contain a TATA-like promoter region (TAL), the firefly luciferase coding 
sequence, SV40 late polyadenylation signal, a transcription blocker (TB),  and an 
ampicillin resistance gene (Ampr). 
 
For each CRE transcription assay, cells were plated in 6-well plates, and grown 
overnight.  For each well, 1 μg plasmid DNA was prepared in 500μl Opti-MEM media, 
combined with 10μL Lipofectamine 2000 (Invitrogen, Carlsbad,CA)  in 500μL Opti-MEM, and 
incubated for 20 min before being applied to plated cells. After 8 hours, the cells were switched 
to low-serum media for 24 hours prior to the experiment. For calcium phosphate transfections 
using the CalPhos Mammalian Transfection kit (Clontech, PaloAlto, CA), 1 μg of plasmid DNA 
was combined with water and Calcium Phosphate reagent, allowed to incubate 20 minutes at 
room temperature, and then added drop-wise to cells.  Transfections were allowed to proceed 
overnight before switching to low-serum media for 24 hours prior to use. Parallel experiments 
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were performed using either Lipofectamine 2000 or calcium phosphate, with similar results.  
However, since the Calcium phosphate method resulted in less injury to the cells, this was the 
method most often employed. 
3.2.2 Luciferase Assay 
Cells were assayed for CRE reporter activity using a Luciferase Reporter Assay Kit (Clontech, 
PaloAlto, CA).  Briefly, cells were washed with PBS (without calcium and magnesium) and then 
lysed using 1X Reporter Assay Kit cell lysis buffer using gentle agitation for 20 minutes. Cell 
lysates were then collected with cell scrapers, anc centrifuged briefly (500g, 2 minutes) to 
remove cellular debris. After centrifugation, supernatants were assayed for luciferase activity 
within 20 minutes or frozen at –70oC and assayed within 3 weeks. Equal volumes of lysate, 
buffer and luciferin substrate were combined (200 μl final volume), followed by a 20 second 
measurement of emitted light using a Lumat LB 9507 tube luminometer (Berthold Technologies 
USA, Oak Ridge, TN). Luciferase, expressed in response to CRE transactivation, catalyzes the 
oxidation of luciferin, resulting in photon production. Light output is directly proportional to 
amount of luciferase, and thus transcriptional activity driven by CRE in the cells. Relative light 
units were normalized to the untreated control for all experiments.   Additionally, as a further 
control, for some experiments protein concentrations of cell lysates was determines, and used to 
normalize activity across wells. 
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3.2.3 Toxicity Assays 
For each assay, 6-OHDA (Sigma, St. Louis, MO) was prepared in ice cold 0.5% (wt/vol) 
ascorbate or sterile water immediately before use. Since equivalent results were obtained with 
either vehicle system, sterile water was used preferentially.  Dibutyryl-cyclic-adenosine 
monophosphate (db-cAMP) (Sigma, St. Louis, MO) was prepared in sterile water, and was also 
prepared fresh immediately prior to each experiment.  To determine protection, reagents 
(catalase (30U/ml) or db-cAMP (250 μM-500μM)) were dissolved in cell culture media, and 
added to cells at times and concentration indicated in figure legends. Toxicity was measured 
using a Lactate dehydrogenase (LDH) release assay (Sigma 340-UV LDH detection system). 
Briefly, cells were grown in 96-well plate format and exposed to a dose curve of concentration of 
6-OHDA (0-1400 μM for B65 cells; 0-300 μM for SH-SY5Y cells) or to vehicle for 18-20 
hours. Following visual inspection of cell morphology, cells were centrifuged (5 minutes, 500g) 
and aliquots of supernatant were obtained. An equal volume of 2% (wt/vol) Triton X-100 was 
added to the wells and cells were lysed by gentle pipetting followed by a 30 minute incubation at 
37oC.  The amount of LDH activity in the supernatant (“released” LDH) and lysate (“total” 
LDH) were determined by measuring the decrease in absorbance at 340nM associated with the 
reduction of pyruvate in a linear velocity reaction.  The level of LDH release into the culture 
medium was expressed as percent of total LDH in the wells. 
To determine if any of the toxicity treatments elicited caspase activation, a Caspase 3 
activity assay was used.  Briefly, B65 and/or SH-SY5Y cells were grown and treated as 
described.  To separate nuclear and cytoplasmic protein fractions, the NePUR Kit (Pierce, 
Rockford,IL) was used as directed by the manufacturer, and cytoplasmic fractions only were 
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analyzed. Prior to use, the lysates were then centrifuged for 30 min at 4°C, 16 000 g, and after 
centrifugation, protein concentrations of the supernatants were ascertained using the Bio-Rad 
Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Samples containing 100 µg protein were 
mixed with 20 µM of the fluorogenic substrate Acetyl-Asp-Glu-Val-Asp-7-amido-4-
trifluoromethyl-coumarin (Chemicon International, Temecula, CA, USA), followed by a 2-h 
incubation at 37°C. The changes in fluorescence were quantified every 20 min using a 
luminescence spectrometer (Winlab; Perkin Elmer, Shelton, CT, USA) (excitation 400 nm, 
emission 505 nm).  
3.2.4 Cell Viability Assays   
To assay cell viability, the metabolic dye alamarBlue (Biosource, Camarillo, CA) was utilized.  
As a redox indicator, alamarBlue is reduced by reactions innate to cellular metabolism and, 
therefore, provides an indirect measure of viable cell number. Reduction was determined  by 
measuring fluorescence as a function of time. Fluorescence measurements were made by 
exciting at 530-560 nm and measuring emission at 590 nm. In reporting alamarBlue reduction, 
data are expressed as fluorescence emission intensity units as a function of time of incubation.  
Briefly, for each assay, cells were plated in 96-well plates and treated with db-cAMP and 6-
OHDA as indicated above and in figure legends.   After 18-24 hours, alamarBlue (1:10 dilution) 
was added to the plates, and fluorescence at time zero was measured to obtain a baseline.  
Fluorescence was measured again after a 2-hour incubation at 37o.   After baseline subtraction, 
cellular fluorescence is an indicator of cell survival.   
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3.3 PROTEIN AND RNA PROCEDURES 
3.3.1  Protein Isolation 
Total cell lysates were obtained at various time points using a lysis buffer containing Triton X-
100, and protease and phosphatase inhibitors  (Sodium Orthovanidate (1mM final concentration), 
PMSF (1.25mM), Sodium Pyrophosphate, (2mM), and E-64 (100uM)). Briefly, after treatments 
cells were washed in 1X scraping buffer (25mM Hepes, 50mM NaCl, 5mM EDTA, pH 7.5) to 
remove traces of remaining media, and then collected in appropriate volume of scraping buffer 
and centrifuged (1000 RPM) for 5 minutes.  All steps were performed on ice or at 4oC. After 
centrifugation and removal of supernatent, cell pellets were resuspended in 40-100uL Lysis 
buffer (25mM Hepes, 150mM NaCl, 5mM EDTA, 100mM Triton-X 100, pH 7.5) and pipetted 
vigorously to disrupt cell membranes.  After a 30 minute incubation on ice, lysates were 
centrifuged briefly to pellet debris and stored at –80oC until use.   
To separate nuclear and cytoplasmic protein fractions, the NePUR Kit (Pierce, 
Rockford,IL) was used as directed by the manufacturer. Protein concentration was determined 
using the Coomassie Plus Protein Assay (Pierce, Rockford,IL), and the purity of the fractions 
was assessed by immunoblotting for cytoplasmic and nuclear markers (Beta-Actin and Lamin, 
respectively).  
3.3.2 Immunoblotting.  
For both total cell protein and nuclear/cytoplasmic fractions, equal amounts of protein were 
electrophoresed through 5-15% SDS-PAGE gels under reducing conditions, transferred to 
 32 
Immobilon-P membranes (Millipore, Bedford,MA), and blocked in 5% non-fat dry milk in PBST 
(20mM potassium phosphate, 150mM potassium chloride, and 3% (w/v) Tween 20, pH 7.4), for 
1-2 hours at room temperature.  Blots were probed overnight at 4oC with the following 
antibodies and dilutions:  
 
Table 1.    Information for antibodies used in Western blots. 
 
AB Target 
 
Vendor 
 
Source 
Species 
 
Dilution 
 
Secondary 
AB 
Phospho-
CREB 
Cell 
Signaling mouse 1:1000 
Anti-mouse 
1:5000 
Total CREB Cell Signaling rabbit 1:1000 
Anti-rabbit 
1:5000 
B-Actin Sigma mouse 1:10,000 Anti-mouse 1:10,000 
Lamin Cell Signaling rabbit 1:1000 
Anti-rabbit 
1:5000 
CBP Cell Signaling rabbit 1:1000 
Anti rabbit 
1:5000 
 
 
CREB control extracts (Cell Signaling) were used as positive control. After washing, blots 
were probed with a HRP-conjugated IgG secondary antibody, and antibody detection was 
carried out using a chemiluminescence detection kit (ECL, Amersham, Piscataway,NJ).   Blots 
were stripped in stripping buffer (50mM sodium dodecyl sulfate (SDS), 25mM glycine, pH 2) 
for 20-30-minutes, washed in PBS and then re-probed with new antibodies as indicated in the 
figure legends.  After use, blots were stained with Coomassie Blue to confirm equal protein 
loading and efficient transfer.   
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3.3.3 Isolation of RNA and RT-PCR   
Total RNA was isolated from treated B65 cells using Qiagen RNeasy Kits (Qiagen, Valencia, 
CA).  RNA was quantified by spectrophotometry and 1 μg RNA was used for each PCR 
reaction.  Primers were designed using the on-line Primer 3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi), unless otherwise stated.  The sequences of forward and reverse 
primers were as follows  (Table 2): 
 
Table 2.    List of Oligos used for RT-PCR. 
Gene       Forward Primer (5’-3’)       Reverse Primer (5’-3’)
 Bcl-2
BDNF GTGACAGTATTAGCGAGTGGG GGGTAGTTCGGCATTGC
CREB TCAGCCGGGTACTACCATTC CCTCTCTCTTCGTGCTGCT
B-Actin TGTTTGAGACCTTCAACACC TAGGAGCCAGGGCAGTAATC
GAPDH GGGTGGTGCCAAAAGGGTC GGAGTTGCTGTTGAAGTCACA
MKP 3 GGCAAAAACTGTGGTGTCCT CCAGGGTCCTTTCAAAGTCA
 
Samples were amplified in a PTC-100, Programmable Thermal Controller (MJ Research, 
Inc. (BIORAD) Waltham, MA), using the GeneAmp EZ rTth RNA PCR Kit (Perkin Elmer/ 
Roche, Branchburgh, NJ) following manufacturers instructions. Reaction products were 
electrophoresed through 1% agarose gels and stained with ethidium bromide.  To determine 
density of visualized bands, gels were scanned in and photographed using a on Kodak Gel Logic 
2200, and Kodak Imaging Software 4.0.4 was used to perform densitometry on observed bands. 
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Typically, date is expressed as a ratio between the densitry of the b-actin band and the band of 
interest.  
Quantitative RT-PCR was performed using a LightCycler Instrument (Roche Molecular 
Biochemicals, Indianapolis, IN), and the LightCycler-RNA Amplification Kit SYBR Green I 
(Roche Molecular Biochemicals, Indianapolis, IN) to measure RNA in a one step RT-PCR 
reaction in real time, following manufacturers instructions. Melting curves and gel 
electrophoresis of the products were used to insure specificity of amplification products.  
3.3.4 Electrophoretic mobility shift assay  
EMSA was performed as described (Oury et al. 2002) on double stranded oligonucleotides by 
hybridizing complementary denatured single stranded oligonucleotides with10X annealing buffer 
(200 mM Tris-HCl pH8.0, 100 mM MgCl2, 500 mM NaCl). An established palindromic CRE 
probe sequence (5’-AGAGATTGCCTGACGTCAGAGAGC-3’) (Chandran et al. 1996) was 
used.  This CRE consensus sequence, taken from the rat somatostatin gene promoter, has been 
used extensively in the literature (Zhang et al. 2004)and (Hershko et al. 2003) and is also 
commercially available (Promega, Madison, WI). The CRE probe (32P end labeled; 20,000 cpm 
per lane) was incubated with 30 μg of nuclear protein extract in 5X binding buffer (50 mM Tris-
HCl pH8.0, 62.5% glycerol, 2.5 mM EDTA, 750 mM KCl) in a 30 μl total reaction volume for 
15-20 minutes at 25°C. Specificity was assessed by competition with unlabeled CRE probe. 
Poly-dIdC (15 ng) was used as a nonspecific competitor. For supershift assays, a mixture of 
antibodies to CREB and Ser133 phosphorylated CREB (pCREB) (3uL each) was added 15 
minutes prior to the addition of labeled CRE probe.   Protein-DNA complexes were resolved on 
a 1X TBE/ 10% PAGE, and detected by autoradiography. 
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3.4 MICROSCOPY STUDIES 
3.4.1 Immunocytochemistry   
B65 and SH-SY5Y cells were plated on glass coverslips in 12-well plates at a density of 1.5x105 
cells/well, treated with 6-OHDA or cAMP as indicated in figure legends, then washed with 
phosphate-buffered saline (PBS) and fixed in ice-cold 4% paraformaldehyde for 15 minutes (Chu 
et al. 2005). Cells were permeabilized with 0.1% Triton X-100/PBS, and then blocked in 5% 
normal donkey serum. To visualize phosphorylated CREB, a pCREB monoclonal antibody 
(1:1000, overnight at 4°C, Cell Signaling) was used.  Coverslips were then washed with PBS and 
incubated with Cy3-conjugated secondary antibodies (1:200, Jackson ImmunoResearch) for 1 
hour at room temperature. Nuclei were counterstained with DAPI (Molecular Probes).  For 
additional experiments, the mitochondrial voltage-dependent ion channel marker, anti-ANT 
(Adenine nuclerotide transporter) (1:200, Santa Cruz Biotechnilogy, INC, Santa Cruz, CA) was 
used in a triple label.  Coverslips were mounted in gelvatol, and cells visualized and 
photographed using an Olympus Provis fluorescence microscope (Olympus America Inc., 
Melville, NY, USA) equipped with three filter cubes: FITC (excitation 490/emission 520), 
TRITC (excitation 541/emission 572 nM) and DAPI (excitation 350/emission 470 nM). 
Primary cell cultures were obtained as described above.  For immunofluorescence 
studies, cells were treated with 6-OHDA and/or db-cAMP for 3 hours as indicated, and then 
immediately fixed in 4% paraformaldehyde for 15 minutes. After rinsing with PBST, cells were 
blocked in 5% Donkey Serum for 1 hour at room temperature, then probed with indicated 
antibodies.  For striatal cultures, cells were co-labeled with antibodies against pCREB (1:1000) 
and the neuronal marker neurofilament (polyclonal, 1:500, Sigma, St. Louis, MO).  For midbrain 
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cultures, cells were co-labeled with antibodies against pCREB, and TH to label dopaminergic 
neurons (polyclonal, 1:2000, Chemicon, Temecula, CA).  After washing in PBST, cells were 
incubated in appropriate secondary antibodies, anti-mouse Cy3 and anti-rabbit Alexa 488, at 
1:500 in Link Diluent (BioGenex, San Ramon, CA).   For all cultures, the cells were 
counterstained with the nuclear marker DAPI (4',6-diamidino-2-phenylindole, dihydrochloride) 
(Molecular Probes). The slides were observed using an Olympus Provis fluorescence microscope 
(Olympus America Inc., Melville, NY, USA) and/or a Nikon Eclipse II microscope.  
3.4.2  Immunohistochemistry 
Paraffin-embedded human midbrain sections, from a previously characterized subset of 3 
Parkinsonian and 2 control brains (Callio et al. 2005) (Zhang et al. 2004), were stained for 
pCREB using previously described protocol (Jordan-Sciutto et al. 1999).  Briefly, sections were 
deparaffinized using a series of zylene and ethanol washes, and treated with 3% H2O2 for 30 
minutes to quench endogenous peroxidases.  Sections were then heated in target retrieval 
solution (DAKO Target Retrieval Solution, Carpinteria, CA) at 95oC for an hour, allowed to 
cool, and then treated with Immunon protein blocking agent (Shandon, Pittsburgh, PA) and 
incubated at 4oC overnight with appropriate antibody in antibody diluent (DAKO Antibody 
Diluent with Background Reducing Components, Carpinteria, CA).   This was followed by 
incubation with biotinylaterd (anti-rabbit or anti-mouse secondary where appropriate) IgG 
(1:500, Jackson ImmunoResearch, West Grove, PA) at room temperature for one hour and then 
streptavidin-horseradish peroxidase (1:500).  For tyramine amplification, biotinyl tyraminde 
(1:100, TSA; Perkin-Elmer, Emeryville, CA) was applied for 30 minutes at room temperature, 
followed by streptavidin-horseradish peroxidase (1:500), as described by the manufacturer. The 
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peroxidase reaction was visualized using 3-amino-9-ethyl-carbazole (AEC) substrate (BioGenex, 
San Ramon, CA) and sections were then counterstained with Mayer’s hematoxylin. Equivalent 
results were obtained using avidin-biotin or tyramide amplification.  Slides were visualized and 
photographed, and examined for positive staining. 
3.5 STATISTICAL ANALYSIS 
All results are expressed as mean ± SEM unless otherwise indicated. Two-group comparisons 
were performed using Student's t-test. Multiple-group comparisons were performed using 
ANOVA. Post hoc testing used the Student's t-test with Bonferroni correction, and p < 0.05 was 
accepted as statistically significant. 
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4.0  RESULTS 
4.1 CRE/CREB FUNCTION 
4.1.1 6-OHDA Represses the CRE Promoter 
The luciferase reporter transcription assay was used to monitor induction of the CRE element in 
B65 cells treated with media, db-cAMP, 6-OHDA or vehicle.  Luciferase is expressed in 
response to CRE transactivation, and will catalyzes the oxidation of the substrate luciferin (added 
during the assay), resulting in photon production. Light output is directly proportional to amount 
of luciferase present in each sample, and thus is a measure of CRE transcriptional activity in the 
cells.  Luciferase activity from 6 independent experiments were normalized to the untreated 
control of each experiment, and averaged (Figure 3). Results show treatment with db-cAMP (a 
cell permeable cAMP analog, and potent activator of CRE) resulted in a 2.5 fold induction of the 
CRE promoter, while treatment with 6-OHDA caused a significant repression in the basal 
activity of the CRE promoter.  Control cells stimulated with vehicle alone did not show 
significantly different responses from untreated cells.  
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 Figure 3.    6-OHDA treatment causes repression of the CRE promoter. 
The CRE-luciferase reporter vector was used to monitor induction of the CRE element.  
Cells were transfected with pCRE-luc as described in Methods, then stimulated with media 
alone (UT), cAMP, 6-OHDA or ascorbate vehicle for 3 h and assayed for luciferase activity 
as described in Methods.  Data is expressed as the fold induction of luciferase activity 
normalized to the untreated control group, and represents the mean of 6 independent 
experiments, +/- standard deviation. *p < 0.05 (ANOVA followed by Student's t-test with 
Bonferroni correction). 
 
Next, to verify that the observed repression was not due to cell death, several measures of 
cell viability and the transcription of control luciferase constructs lacking CRE elements (Figure 
4) were examined. At the time points used for transcriptional assays (30 min to 3 hours of 6-
OHDA exposure) no morphological changes of cell death are apparent (Figure 4B). Cells treated 
with 6-OHDA for 3 hours looked as robust and healthy as untreated cells.   Moreover, there is no 
evidence of LDH release at 4 hours of 6-OHDA exposure (Figure 4C), indicating that cells have 
not begun to lyse at this time point.  LDH release is not apparent until 8 h after 6-OHDA 
initiation indicating that cell rupture and death begins somewhere between 4-8 hours of 6-OHDA 
treatment in B65 cells. Additional control experiments were conducted using the pTAL plasmid, 
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which lacks CRE sequences, but is otherwise identical to the TATA-like promoter-containing 
CRE reporter vector  (See Figure 2 in Materials and Methods). 6-OHDA treatment had no effect 
on pTAL-driven luciferase expression (Figure 4A), indicating that 6-OHDA is not causing a 
general disruption in transcriptional responses. Therefore it is likely that the observed 
transcriptional repression is due to disrupted CRE transactivation specifically, and not to general 
defects in transcription or cell viability.   
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Figure 4.    6-OHDA-induced CRE repression is not due to decreased cell viability 
A. Cells were transfected with a control luciferase construct lacking CRE enhancer 
elements as described in Methods, treated as above, and assayed for luciferase activity. 
There were no significant effects of any treatment condition on basal levels of cellular 
transcription.   B. Representative phase contrast images of the cell cultures obtained at 3 h, 
immediately prior to cell lysis for luciferase assays.  No morphologic evidence of cell injury 
or death was observed at this time point.  C. Cells were treated with a range of 6-OHDA 
concentrations for different amounts of time. Cell injury was assayed using the LDH 
release assay. Data represent the average of triplicate wells +/- standard deviation. There is 
no evidence of cell death until 8 h after 6-OHDA exposure. 
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4.1.2 Disruption in CREB function contributes to 6-OHDA induced cell death.   
Next, the potential ability of cAMP treatment to reverse the repressive effects of 6-OHDA on the 
CRE promoter was examined.  Cells were treated with a cell permeable form of cAMP 10 min 
prior to exposure to 6-OHDA.  The results demonstrate that cAMP pre-treatment prevented the 
6-OHDA-induced repression of CRE activity (Figure 5).  Treatment of B65 cells with cAMP in 
the presence of 6-OHDA not only restored CRE activity, but resulted in CRE activity levels that 
were higher than those elicited by treatment with the same concentration of cAMP alone.  
 
 
Figure 5.     cAMP pre-treatment reverses 6-OHDA-induced repression of CRE. 
Cells were transfected with pCRE-luc plasmid, then stimulated with vehicle, cAMP, 6-
OHDA or 6-OHDA following a 10 min pre-treatment with cAMP. After 3 h, cells were 
lysed and luciferase activity measured. Data is the mean +/- standard deviation, and is 
representative of 5 independent experiments. *p < 0.05 by ANOVA followed by Student's t-
test with Bonferroni correction. 
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Since cAMP reverses the 6-OHDA-induced CRE repression, experiments were 
conducted to determine if cAMP treatment during 6-OHDA exposure would also confer 
protection against 6-OHDA-mediated toxicity. Since the antioxidant catalase has been previously 
shown to protect cells from 6-OHDA – induced injury, it was used here as a positive control 
(Kulich and Chu 2001). Indeed, a 10 minute pre-treatment with cAMP resulted in significantly 
decreased cell injury at 18 h by both LDH release assay and morphological examination (Figure 
6A & B).  This cAMP-induced protection was apparent at a range of 6-OHDA concentrations, 
determined by LDH Assay (Figure 6C), and morpholoical examination (Figure 7).  Since 
addition of cAMP reversed the 6-OHDA-induced repression while conferring protection, these 
data suggest that disruption in CRE function contributes to 6-OHDA-induced cell death.   
 
 
A 
B 
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Figure 6.   cAMP protects against 6-OHDA- toxicity. 
 
A. B65 cells were treated for 10 min with media (None), cAMP (250uM)or catalase 
(30U/ml) before exposure to vehicle or 6-OHDA for 18 hours. Cell injury was assayed using 
the LDH release assay, and are representative of at least 3 independent experiments. *p < 
0.05 vs. 6-OHDA with no pre-treatment (Student's t-test).  B. Cells were photographed 
immediately prior to performing the LDH assay, showing that cAMP pre-treatment results 
in greater numbers of viable neuronal cells (right) compared to the shrunken, dead 
morphology observed with 6-OHDA alone (left).  C.  Cells were exposed to a dose curve of 
6-OHDA treatment and LDH release was examined as described above.  Data is 
representative of 4 independent experiments. 
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Figure 7.    Morphological Evidence of cAMP and Catalase protection from 6-OHDA-induced Toxicity at a 
Range of Concentrations. 
 
B65 cells were treated for 10 min with media (None), cAMP (250uM) or catalase (30U/ml)  
before exposure to vehicle or 6-OHDA for 18 hours. Cell injury was assessed my 
morhological examination.  It is clear that cAMP-treated cells appear more healthy, and 
have less evidence of injury than the cells treated with media alone. The anti-oxidant 
catalase was used as a positive control for protection. 
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4.1.3 Delayed administration of cAMP reverses CRE repression and confers protection. 
This effect was further characterized by determining whether delayed treatment with cAMP 
following initiation of 6-OHDA toxicity would still effectively reverse 6-OHDA-mediated CRE 
repression.  We exposed the CRE-transfected B65 cells to cAMP at different intervals of time 
after 6-OHDA exposure.  Results showed that delayed addition of cAMP indeed caused a 
reversal of 6-OHDA-induced repression (Figure 8A), an effect that was obvious up to one hour 
after toxin treatment.  Moreover, delayed cAMP treatments also resulted in significant protection 
against toxicity even when administered up to 4 hours after initiation of 6-OHDA treatment 
(Figure 8B), further supporting the interpretation that perturbations to the CREB signaling 
pathway contributes to 6-OHDA toxicity.  
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 Figure 8.    Delayed cAMP administration following 6-OHDA treatment reversed CRE repression 
and rescues cells from toxicity. 
 
A. Cells were transfected with pCRE-luc plasmid and treated with 6-OHDA and/or cAMP 
as indicated. The cAMP was added 10 min prior to 6-OHDA (pre), simultaneously with 6-
OHDA (co), or at different intervals after initiation of 6-OHDA injury. After 3 h, cells were 
lysed and luciferase activity measured. Data is the mean +/- standard deviation, and is 
representative of at least 3 independent experiments. *p < 0.05 vs. 6-OHDA alone (ANOVA 
followed by Student's t-test with Bonferroni correction).  B. Cells were pre-treated with 
cAMP 10 minutes prior to 6-OHDA, or at different intervals after initiation of 6-OHDA 
injury. After 18 h, cell death was measured using the LDH release assay. Data represents 
the mean +/- standard deviation from at least three independent experiments. *p < 0.05 vs. 
6-OHDA alone (ANOVA followed by Student's t-test with Bonferroni correction). 
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We next looked to determine if administration of BDNF would protect B65 cells from 6-
OHDA.  Since BDNF is a CRE-mediated gene and is well known for its role in neuronal survival 
(Mayr and Montminy 2001),  and CRE-mediated transcription is repressed in response to 6-
OHDA, we hypothesized that pre-treating cells with BDNF would diminish the cytotoxic effects 
of 6-OHDA.  However, this was not the case, as BDNF treatment had no effect on 6-OHDA-
induced cell death (Figure 9).  
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Figure 9.   BDNF does not confer protection from 6-OHDA-induced toxicity. 
B65 cells were treated for 10 min with media (None) or BDNF (250 or 500nM) before 
exposure to vehicle or 6-OHDA for 18 hours. Cell injury was assayed using the LDH 
release assay, and are representative of at least 3 independent experiments. These results 
are representative of 2 independent experiments. 
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4.1.4   6-OHDA reduces expression of CRE-regulated genes: 
To confirm that 6-OHDA-induced repression of CRE transactivation was associated with 
functional effects on endogenous genes, we examined the expression of downstream CRE-
regulated genes (Mayr and Montminy 2001). BDNF and Bcl-2 were selected due to their well-
documented roles in neuronal growth and survival as well as prior studies showing that both 
CREB-induced genes can protect from 6-OHDA toxicity (Jordan et al. 2004) (Klein et al. 1999). 
Semi-quantitative and quantitative RT-PCR showed decreased BCL2 and BDNF mRNA in 
response to 6-OHDA treatment (Figure 10).  No changes were observed in the mRNA levels of 
MAPK phosphatase-3 (MKP-3), which lacks CRE sequences in its promoter region, or in β-actin 
mRNA levels.   
In addition, stimulation of CRE by cAMP prevented the 6-OHDA-induced reduction in 
mRNA expression of both Bcl2 and BDNF (Figure 10, see lanes labeled “Both”), with cAMP 
and 6-OHDA co-treatment resulting in BDNF and Bcl2 gene expression that was even higher 
than baseline, or with cAMP stimulation alone.  Since previous results showed cAMP pre-
treatment also conferred significant protection (see Figures 6,7), these data indicate that 6-
OHDA-mediated repression of CRE transactivation results in decreased expression of CRE-
controlled survival genes during 6-OHDA-induced neuronal cell death, an effect that may be 
contributing to the cell death process. 
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Figure 10.  6-OHDA results in decreased BDNF and Bcl-2 mRNA expression, which is reversed by 
cAMP. 
 
A. B65 cells were treated with combinations of 6-OHDA and cAMP as indicated and 
subjected to RT-PCR analysis as described in Methods. Note the decreased levels of BDNF 
and Bcl-2 mRNA in 6-OHDA treated cells, which is reversed by addition of cAMP.  In 
contrast, there are no changes in the mRNA levels of MKP-3 or -actin, two genes that 
lack CRE elements in their promoter regions. Gels are representative of three independent 
experiments. B. For quantitative RT-PCR, cells were treated as above and analyzed by real 
time RT-PCR using the Roche LightCycler SYBR Green I system. Data was analyzed with 
relation to  actin crossing points using the ΔΔCt method (Livak and Schmittgen 2001). 
Each graph reflects the average of three independent experiments. *p < 0.05 vs. UT/Both 
(ANOVA & Student's t-test with Bonferroni correction). 
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Interestingly- the promoter of the CREB gene itself also contains a CRE site, and CREB 
activation (via phosphorylation) allows CREB to positively regulate its own expression (Mayr 
and Montminy 2001). Therefore, message level for CREB were also examined.  As 
hypothesized, qualitative RT-PCR showed that levels of CREB mRNA were decreased in 
response to 6-OHDA (Figure 11).  This decrease was not as strong as seen with other CRE-
mediated genes, Bcl2 and BDNF, however, the minor decrease was reversed by cAMP co-
treatment. 
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Figure 11.    6-OHDA treatment resulted in a decrease in CREB mRNA expression. 
 
A. B65 cells were treated with combinations of 6-OHDA and cAMP as indicated and 
subjected to RT-PCR analysis as described in Methods. B. The graph on the right shows 
densitomitry analysis of the observed bands. Note the decreased levels of CREB mRNA in 
6-OHDA treated cells, which is reversed by addition of cAMP.  In contrast, there are no 
changes in the mRNA levels of -actin, which lacks a CRE element in its promoter regions.  
Data are reprecsentative of two independent experiments. 
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4.1.5 Electromobility shift assay demonstrates decreased CRE binding activity in 6-
OHDA treated cells.  
Next, to determine the effect of 6-OHDA on CRE DNA binding activity, nuclear extracts from 
B65 cells treated with 6-OHDA and/or cAMP for 3 h were incubated with radiolabeled DNA 
containing a palindromic CRE sequence. This consensus CRE sequence has been used 
extensively in the literature and is also commercially available (See Materials and Methods).  
Use of specific (unlabeled probe) and nonspecific (poly-dIdC) competitors revealed a specific 
protein-CRE doublet. Treatment with 6-OHDA resulted in decreased CRE binding activity of 
both bands compared to control and cAMP treated cells (Fig. 12A). Supershift assay using a 
mixture of CREB antibodies confirmed the presence of CREB/pCREB in the complex (Fig. 
12B). Interestingly, cAMP co-treatment did not reverse the decrease in CRE binding activity 
observed in 6-OHDA treated cells, despite its ability to reverse CRE-transcriptional repression, 
as indicated by CRE-luciferase and quantitative RT-PCR data shown above. It is possible that 
the kinetics of cAMP-mediated changes do not correspond with the time point analyzed. A more 
likely explanation is that complex multifactorial interactions (co-activators and repressors) 
underlie the ability of cAMP to reverse 6-OHDA mediated transcriptional repression. 
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Figure 12.    Electrophoretic mobility shift assay of CRE-binding activity in B65 cells. 
 
A. Nuclear extracts prepared from B65 cells that were untreated or treated with dibutyryl-
cAMP alone/or prior to 6-OHDA for 3 h were incubated with a 32P-labeled CRE probe for 
15-20 minutes at room temperature.  Where indicated, incubations were performed in the 
presence of a 5-fold, 10-fold or 50-fold molar excess of unlabeled CRE probe to inhibit the 
specific band (panel A), in the presence of poly-dIdC to inhibit the nonspecific bands (n.s., 
panel A), or in the presence of CREB antibodies to supershift the protein-CRE complex 
(panel B). The migration of protein-bound CRE probe is retarded relative to that of the 
free CRE probe. B. To determine whether the protein-CRE complexes included CREB, 
antibodies were used to supershift the complexes. Arrows indicate the relative migration of 
protein-bound CRE with and without the CREB antibodies.  
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4.1.6 The Protective effects of cAMP work though PKA. 
To determine whether the effects of cAMP were mediated through activation of protein kinase 
A, cells were treated in the presence of a protein kinase A inhibitor H89 (10mM, (Sanchez et al. 
2001)). The presence of H89 suppressed cAMP-mediated increases in CRE-luciferase activity to 
baseline levels in cells co-treated with cAMP and 6-OHDA (Figure 13).  These results suggest 
that the transcriptional effects of cAMP are mediated through protein kinase A, although 
additional mechanisms affecting 6-OHDA-mediated repression cannot be excluded. 
   
Figure 13.    H89 supresses cAMP-mediated increases in CRE-luciferase activity. 
 
B65 cells transfected with CRE-luciferase were treated with cAMP, 6-OHDA (6OH), or 
both cAMP and 6-OHDA, in the absence or presence of the PKA inhibitor H89 (10 M). 
After 3 h, lysates were collected for luciferase assay, and the results normalized to 
untreated control cultures. 6-OHDA caused significant repression of CRE-luciferase 
expression, which was not reversed by H89. H89 co-treatment significantly inhibited effects 
of cAMP alone and the effects of cAMP on cells treated with 6-OHDA. * p < 0.01 versus 6-
OHDA/cAMP. † p < 0.01 versus cAMP. 
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Additionally, the effects of inhibitors of both the PKA pathway (H89) and of the ERK 
pathway (PD098059 and OU126) on the basal levels of CRE activity in B65 cells were 
examined.  Since CRE-mediated can be activated by multiple pathways in neuronal cells, we 
sought to determine the relative contribution of these two main CREB-activating pathways to 
baseline CRE stimulation in growing neurons.  Interestingly, MEK inhibitors repressed basal 
levels of CRE activation  (Figure 14 A,B), while the PKA inhibitor had no effect (Figure 14 C).  
These results suggest that cellular processes activated during neuronal growth in culture function 
primarily through the ERK pathway, with the PKA path making only a very minor, if any,  
contribution. 
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Figure 14.   The MEK inhibitors, UO126 and PD98, represses CRE transactivation, but the PKA 
inhibitor, H89, does not. 
 
B65 cells were transfected with CRE-luciferase and treated with cAMP. 6-OHDA, UO126, 
PD098059 or PKA , depending on experiment, and as indicated in figure legends.  After 3 
hours, lysates were collected for luciferase assay and results were normalized to the 
luciferase activity in the untreated control cultures for each experiment. Both PD and 
UO126 repressed CRE luciferase activity, and H89 had no effect. 
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4.1.7 CONCLUSIONS 
The oxidative neurotoxin, 6-OHDA, is toxic to the B65 neuronal cell line.  We have determined 
that 6-OHDA represses the CRE promoter, and reversal of that repression with cAMP treatment 
protects cells from toxicity.  This protection was evident even with delayed cAMP 
administration, up to 4 hours following 6-OHDA treatment.  The observed repression had a 
functional effect, as downstream CRE-mediated genes, BDNF, Bcl2, and CREB were all 
decreased in response to the toxin.  Restoration of gene expression occurred  with cAMP 
stimulation, an effect that was associated with protection from death.  When DNA binding was 
examined using EMSA, we see that 6-OHDA decreases in CRE binding activity.  Interestingly, 
the PKA inhibitor, H89, did not affect basal CRE activity.  However, inhibition of the ERK 
pathway (via MEK inhibitors, PD098059 and OU126)  did results in CRE repression, indicating 
that basal CRE activity is working, at least in part, through the ERK and not PKA.  Additionally, 
since camp-mediated reversal of 6-OHDA induced CRE repression  could be blocked with H89, 
this indicates that the protective effects of camp observed in this cell line occur through PKA.  In 
the next set of experiments,  potential mechanisms for these observed results were examined. 
4.2 CREB LOCALIZATION 
4.2.1 Effects of 6-OHDA treatment on CREB phosphorylation and localization. 
To further investigate potential mechanism(s) underlying CRE repression, we examined the 
expression levels and subcellular localization patterns of CREB and pCREB in B65 cells. In 
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contrast to studies in other systems that showed decreased CREB phosphorylation as the major 
mechanism of signaling pathway repression (See and Loeffler 2001) (Ito et al. 1999), 6-OHDA 
treated cells exhibited a clear increase in pCREB (Figure 15A), using whole cell lysates.   
Since CREB can be activated in the cytoplasm by phosphorylation of Ser-133 before 
translocating to the nucleus to control gene transcription (Stevenson et al. 2001), we performed 
subcellular fractionation studies. Time course studies revealed that 6-OHDA caused progressive 
accumulation of pCREB in the cytoplasm (Figure 15C), with a mild, but persistent decrease in 
nuclear fractions of 6-OHDA treated cells (Figure 15B). A similar pattern was observed using an 
antibody that recognizes CREB irrespective of its phosphorylation state (FIGURE 16). The 
altered subcellular distribution of pCREB in 6-OHDA treated cells likely contributes to the 
functional repression of CRE transactivation, despite increased total levels of pCREB.  
Interestingly, the addition of protective doses of cAMP to 6-OHDA treated cells ameliorated the 
decrease in nuclear pCREB, but had little effect on pCREB accumulation in the cytoplasm 
(Figure 15B & C, last lane). 
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 Figure 15.   Effects of 6-OHDA treatment on subcellular distribution of pCREB. 
 
A. Total Triton-X100 cell lysates were prepared following treatment with the indicated 
combinations of cAMP and 6-OHDA, and subjected to western blot analysis for pCREB. B. 
Nuclear fractions were prepared from cells treated with cAMP and 6-OHDA for the 
indicated time points, and analyzed for pCREB, then stripped and reprobed for the 
nuclear marker lamin A. C. Cytoplasmic fractions were prepared from cells treated with 
cAMP and 6-OHDA for the indicated time points, and analyzed for pCREB, then stripped 
and reprobed for b-actin as a loading control. Data is representative of at least 3 
independent experiments. 
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Figure 16.  Effects of 6-OHDA on Total-CREB. 
 
Cytoplasmic and nuclear fractions were prepared from cells treated with cAMP and 6-
OHDA for the indicated time points, and analyzed for total CREB.  Blots were then 
stripped and re-probed for b-actin as a loading control. Data is representative of at least 3 
independent experiments. 
 
 
Since binding of co-factors is often critical for stimulus-induced activation of CREB in 
various important cell processes, we next looked at the expression levels of CREB-binding 
protein (CBP) in B65 cells in response to 6-OHDA. CBP is a 265 kDa nuclear protein that 
associates with phosphorylated CREB (reviewed in (Goldberg and Barres 2000))and functions as 
a CREB co-activator.  CBP sequestration (and subsequent disruption of function) has been 
shown to be a contributing factor in the pathogenesis of various polyglutamine-mediated diseases 
(Reviewed in (Rouaux et al. 2004). To examine if disruption of CBP played a role in our 
observed decrease in CRE function, we looked at expression levels in nuclear and cytoplasmic 
fractions.  Our data indicate that there was no change in the levels of CREB binding protein 
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(CBP), which was present only in the nuclear fractions (Figure 17). Thus, the altered nuclear-
cytoplasmic distribution of CREB is not due to generalized disruption of all nuclear transcription 
related proteins, nor is a loss of this important CREB co-activator contributing to CRE disruption 
in our model.  
 
 
 
 
Figure 17.   CBP Expression in nuclear fractions of 6-OHDA-treated B65 cells. 
 
Nuclear and cytoplasmic fractions were prepared from B65 cells treated with cAMP and/or 
6-OHDA for the indicated time points, and analyzed for CBP as described in Methods.  
Note that CBP expression in response to 6-OHDA is not changed from the untreated.  CBP 
was not detected in cytoplasmic fractions. 
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4.2.2 Immunofluorescence localization of pCREB in 6-OHDA treated cells. 
The distribution of pCREB was further characterized using immunofluorescence. In control 
cells, there is a low diffuse background level of pCREB staining, which is predominantly 
cytoplasmic in distribution (Figure 18A). The addition of cAMP to otherwise untreated cells had 
no effect on the intensity of pCREB staining in the cells, but increased the numbers of cells 
showing nuclear localization of pCREB (Figure 18B). In contrast, treatment with 6-OHDA for 
three hours resulted in markedly increased cytoplasmic pCREB staining intensity (Figure 18C). 
Co-treatment of 6-OHDA with cAMP promoted nuclear localization of pCREB in a subset of 
cells (Figure 18D).  These in situ techniques support the results obtained from the subcellular 
fractionation studies, and demonstrate that 6-OHDA elicits accumulation of pCREB in the 
cytoplasm. Despite this increase in cytoplasmic pCREB levels, nuclear expression of pCREB 
and transactivation of CRE-containing genes are suppressed during 6-OHDA toxicity. 
 
 
 63 
 Figure 18.   6-OHDA elicits increased cytoplasmic and perinuclear staining for pCREB. 
 
Cells were treated as indicated below.  After 3 h, coverslips were fixed and double labeled 
for pCREB and the nuclear marker DAPI as described in Methods. A. A light, 
predominantly cytoplasmic, staining pattern is observed for pCREB in control cultures. B. 
Addition of cAMP alone promotes nuclear staining for pCREB (arrows, note that pCREB 
staining is diffuse with no evidence of nuclear exclusion in many cells). C. 6-OHDA treated 
cells display increased cytoplasmic staining. D. 6-OHDA/cAMP co-treated cells display 
both increased cytoplasmic staining with exclusion of the nucleus (asterisks) in some cells 
and diffuse nuclear or nuclear-cytoplasmic staining (arrows) in other cells. Data is 
representative of 3 independent experiments. 
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4.2.3 Conclusions 
To examine the potential mechanism underlying 6-OHDA-induced CRE repression, a series of 
immunoblot experiments were preformed.  Data indicate that 6-OHDA causes a diversion of 
CREB/pCREB out into the cytoplasm, and protection from the toxin was associated with 
restoration of nuclear expression.  Expression patters of the important CREB co-activator, CBP, 
were not altered in response to 6-OHDA.  These data suggest that cytoplasmic diversion of the 
important nuclear transcription factor CREB may be a mechanism that underlies the cellular 
processes that are activated during 6-OHDA-induced neuronal death. 
4.3 SH-SY5Y CELLS, PRIMARY NEURONS AND HUMAN TISSUE  
4.3.1 6-OHDA induces CRE repression and decreased nuclear CREB that is reversed by 
cAMP in SH-SY5Y cells.  
The effects of 6-OHDA on CREB signaling was confirmed using a different neuronal cell line. 
SH-SY5Y is a human neuroblastoma cell line that produces dopamine and expresses dopamine 
transporters (Decker et al. 1993). SH-SY5Y cells have been extensively used to model 
dopaminergic neuron injury and death. In this cell line 6-OHDA caused a 50% repression in 
basal CRE-luciferase activity in SH-SY5Y cells (Fig. 19), an effect that concurs with the 6-
OHDA-induced repression seen in B65 cells (See Figure 1).   While co-treatment with cAMP 
completely reversed the 6-OHDA mediated transcriptional repression, co-treatment did not result 
in the degree of increased CRE transactivation observed in B65 cells.    
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 Figure 19.   6-OHDA represses the basal activity of the CRE promoter in SH-SY5Y cells. 
 
A human neuroblastoma-derived dopaminergic cell line was treated with LD50 doses of 6-
OHDA (150 uM) for 3 h. A. In these experiments, cells were transfected with CRE-
luciferase reporter 24 h earlier, and lysates were analyzed in quadruplicate wells for 
luciferase activity. Data is expressed as the fold induction of luciferase activity normalized 
to the untreated control group +/- standard deviation. 
 
We next examined whether co-treatment with cAMP could confer protection against 6-
OHDA-mediated toxicity.  Indeed, a 10 minute pre-treatment with cAMP prior to 6-OHDA 
initiation resulted in significantly decreased cell injury at 18 hours, as shown by LDH assay 
(Figure 20A).  Additionally, a separate cell viability assay (alamarBlue) showed increased cell 
number with cAMP co-treatment, again indicating that reversing 6-OHDA-induced repression 
protected SY5Y cells from cell death. (Figure 20B).  Evidence of protection was observed by 
morphological observation as well (Figure 21). Taken together, these data further support the 
hypothesis that disruption in CRE function contributes to 6-OHDA-induced death in neuronal 
cells. 
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Figure 20.    cAMP Protects SH-SY5Y Cells from 6-OHDA toxicity, as shown by two cell death assay (LDH 
Release), cell viability assay (alamarBlue). 
  
B65 cells were treated for 10 minutes with media or camp (500uM) before exposure to 
vehicle or 6-OHDA (at indicated concentrations) for 18 hours.  A.  Cell injury was assessed 
using the LDH release assay, and results shown are representative of at least 2 independent 
experiments.  B.  Cell viability was assessed using the AlimarBlue assay system.  Increased 
fluorescence is indicative of increased cell viability.  
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 Figure 21.   Morphological Evidence of cAMP Protection of SH-SY5Y Cells from 6-OHDA toxicity. 
 
SH-SY5Y cells were treated for 10 minutes with media alone or camp (500uM), before 
exposure to vehicle  (0uM 6-OHDA) or  6-OHDA at indicated concentrations for 18 hours.  
Cells were photographed and morphology was examined, indicating that cAMP 
pretreatment resulted in a greater number of viable cells. 
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4.3.2 Altered subcellular localization of CREB in SY5Y cells. 
We next examined sub-cellular expression patterns of CREB and pCREB in SY5Y cells.  As in 
B65 cells, Western blot indicates that repression of basal CRE transactivation was accompanied 
by increased cytoplasmic CREB/pCREB and by decreased nuclear CREB/pCREB in SH-SY5Y 
cells (Fig. 22A). Restoration of CRE transcription in cells co-treated with cAMP and 6-OHDA 
was accompanied by increased nuclear pCREB, although levels of total CREB were not 
appreciably altered relative to 6-OHDA alone. Immunofluorescence studies also confirm an 
increase in cytoplasmic pCREB staining in 6-OHDA-treated SH-SY5Y cells (Fig. 22B).  
Interestingly, there was also a change in the cytoplasmic distribution of pCREB. Control cells 
show a light diffuse, finely stippled staining pattern. The addition of 6-OHDA resulted in the 
appearance of a clumped perinuclear staining pattern.  
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 A 
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Figure 22.  6-OHDA treatment results in increased cytoplasmic CREB/pCREB and decreased nuclear 
CREB/pCREB in SH-SY5Y cells. 
 
A human neuroblastoma-derived dopaminergic cell line was treated with LD50 doses of 6-
OHDA (150 M) for 3 h. A. Equal amounts of protein were loaded from cytoplasmic and 
nuclear fractions of lysates from cells treated as indicated. Immunoblot analysis for 
pCREB, total CREB and loading controls were performed. B. SH-SY5Y cells were treated 
with vehicle or 6-OHDA x 3 h and subjected to immunofluorescence for pCREB. Note that 
6-OHDA treated cells display increased cytoplasmic pCREB staining which shows a 
clumped distribution in contrast to the diffuse light pCREB staining in control cells 
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Consistent with previously published studies, 6-OHDA toxicity was accompanied by 
caspase 3 activation in SH-SY5Y cells (Fig. 23A), which is indicative of activation of an 
apoptotic pathway.  This increase in caspase 3 was significantly decreased by cAMP co-
treatment.  Note that 6-OHDA treatment did not elicit caspase 3 activation in B65 cells after 3 
hours of 6-OHDA exposure- Figure 23B). 
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Figure 23.  6-OHDA elicits caspase 3 activity in SH-SY5Y cells, but not B65 cells. 
 
6-OHDA elicits increased caspase 3 activity in SH-SY5Y cells that is significantly 
attenuated by co-treatment with cAMP. Cells were treated with LD50 doses of 6-OHDA 
(150 uM for SY5Y and 500 uM for B65 cell lines) for 3 h. Equal amounts of protein were 
analyzed from cytoplasmic fractions of lysates as indicated in the Methods section. 
*p < 0.05 vs. UT; **p < 0.05 vs. 6-OHDA alone (ANOVA followed by Student's t-test with 
Bonferroni correction). 
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4.3.3  6-OHDA injury to primary dopaminergic neurons is accompanied by loss of 
nuclear pCREB.  
To determine the effects of 6-OHDA toxicity on primary dopaminergic neurons, midbrain 
cultures were derived from embryonic mice as described in Methods. Because the neuronal 
population of interest accounts for 10% of cells in these cultures, assays involving cell disruption 
are difficult to interpret. 6-OHDA treated cultures were triple labeled for pCREB, tyrosine 
hydroxylase to identify dopaminergic neurons, and DAPI as the nuclear marker. In contrast to 
the immortalized neuronal cells, primary neurons exhibit a higher basal expression of nuclear 
pCREB, which was enhanced by cAMP treatment (Fig. 24AB). In contrast, 6-OHDA exposure 
resulted in two staining patterns, both characterized by absence of nuclear pCREB. The more 
common pattern involved granular or clumped cytoplasmic staining for pCREB with exclusion 
from the nuclear outline (Fig. 24C). Other TH neurons exhibited a complete absence of pCREB 
staining all together (Fig. 24C asterisk). Interestingly, non-TH neurons in the cultures, which are 
more resistant to 6-OHDA injury as they lack an active transport mechanisms for the toxin, 
retained robust nuclear pCREB expression (Fig. 24D). Quantitative analysis of nuclear staining 
in TH+ neurons was performed using image analysis protocols described previously to measure 
nuclear versus cytoplasmic staining for another death regulator (Chu et al. 2005). These results 
indicate significant loss of nuclear pCREB in 6-OHDA cells, which was reversed by cAMP 
treatment (Fig. 24E). 
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 Figure 24.    Decreased nuclear pCREB is observed specifically in 6-OHDA treated TH+ neurons, which is 
reversed by cAMP co-treatment. 
 
Primary midbrain cultures from E15 mice were plated on chamber slides and treated with 
50 M 6-OHDA in the presence or absence of cAMP. Nuclear pCREB appears purple due 
to co-localization of the red pCREB signal and blue nuclear counterstain. A. In control 
cultures, both TH+ and non-TH neurons show diffuse nuclear and cytoplasmic staining for 
pCREB. B. Treatment with cAMP results in accentuated nuclear staining for pCREB in 
both TH+ and non-TH neurons. C. 6-OHDA, which is internalized by high affinity 
dopamine transporters on TH+ neurons, selectively decreases nuclear pCREB staining in 
many TH neurons. Cytoplasmic pCREB is preserved, sometimes developing a clumped 
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appearance similar to that observed in SH-SY5Y cells (yellow due to colocalization of red 
pCREB and green TH fluorescence). D. In other TH+ neurons, there is absence of nuclear 
and cytoplasmic pCREB staining (asterisk), but non-TH neurons in the same culture show 
nuclear pCREB (arrows). E. TH+ neurons from four independent chambers per treatment 
condition were scored as either showing nuclear pCREB staining or loss of nuclear pCREB 
staining. Note that 6-OHDA caused a significant decrease in nuclear pCREB at this early 
time point, which is reversed by co-treatment with cAMP.  *p < 0.05 vs. UT; **p < 0.05 vs. 
6-OHDA alone (ANOVA followed by Student's t-test with Bonferroni correction). 
 
4.3.4 Cytoplasmic accumulation of pCREB is observed in dopaminergic neurons of 
human Parkinson's/Lewy body disease patients.  
We previously found that kinases that functioning upstream of CREB and are capable of 
activating CREB were involved in granular or clumped cytoplasmic aggregates in Parkinson's 
disease and the closely related diffuse Lewy body dementia, and that this alteration is an early 
change observed in presymptomatic patients (Zhu et al. 2002). Accordingly, we next sought to 
look downstream of those kinases and examine the expression patterns of pCREB in human 
disease tissue, to determine the relevance of our results in an actual human neurodegenerative 
diseased brain.   Immunohistochemical study of pCREB was performed on a subset of cases 
from this series for which tissue sections were available. In normal brains, pCREB staining is 
limited to glial nuclei (Fig. 25AB) and nuclei of endothelial cells (not shown). In the diseased 
human neurons, there was increased expression of granular or clumped pCREB 
immunoreactivity (Fig. 25, panels C-G) in both pigmented and depigmented (pale body) regions 
of cytoplasm. (Fig. 25FG). This clumped pattern of pCREB expression was reminiscent of the 
pattern observed with pERK in similar diseased tissue (Zhu et al. 2002), and suggest there may 
be a common disruption in nuclear/cytoplasmic trafficking occurring in neurodegenerative 
disease processes.  
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 Figure 25.   Clumped or granular pCREB is increased in the cytoplasm of dopaminergic neurons in 
the substantia nigra of parkinsonian patient brains. 
 
A & B. In elderly control subjects, there is normally no pCREB staining (red) in SNc 
neurons (arrowhead), but staining of glial nuclei (arrow) is seen. Note the brown 
endogenous pigment that characterizes dopaminergic neurons in this nucleus, which is 
readily distinguished from the red chromogen used for the pCREB stain. C, D, E. In 
different Parkinson's/Lewy body disease patient brains, there was increased granular or 
clumped pCREB staining, often in association with regions of depigmentation (pale bodies). 
Positive staining is also observed in glial nuclei (arrows). F & G. The increase in pCREB 
staining was restricted to cytoplasm of SNc neurons, and was not observed in neuronal 
nuclei (arrowheads). Scale: 10 um. 
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4.3.5 Conclusions. 
The effects of 6-OHDA on the B65 neuronal cell line were confirmed in three separate cell 
systems:  the Sh-SY5Y dopaminergic neuronal cell line, primary midbrain neurons, and post-
mortem Parkinson’s Disease brain tissue.  These data show that in all model systems, 6-OHDA 
disrupts CREB signaling.  In SY5Y cells, 6-OHDA causes repression of CRE transactivation, 
and reversal of this effect with cAMP offers protection.  Additionally, 6-OHDA treatment 
resulted in increases in cytoplasmic CREB/pCREB expression, and decreases in nuclear 
immunoreactivity.  Similar alterations in CREB localization were seen in primary midbrain 
neurons, as well as in Parkinson’s/Lewy Body Disease brain tissue, as both exhibited abnormal 
cytoplasmic accumulations of pCREB in injured neurons.  Since previous results in our lab 
showed similar cytoplasmic diversion of important cell signaling proteins, these data describe a 
common deficit in nuclear/cytoplasmic trafficking that is occurring during neuronal death 
processes. 
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5.0  DISCUSSION 
5.1 SUMMARY OF RESULTS. 
 
Oxidative stress is increased in both aging and in age-related diseases of almost every major 
organ system, including the nervous system.  In particular, cells of the central nervous system are 
believed to be particularly susceptible to the damage of oxidants, and continual exposure to 
oxidative stress over the years may wear down neurons’ antioxidant responses (Cassarino and 
Bennett Jr. 1999) However, mechanisms that contribute to impaired cellular adaptation to 
oxidative neuronal injuries remain to be fully defined.  Using two CNS-derived neuronal cell 
lines, we have determined that the oxidative neurotoxin 6-OHDA causes a decrease in 
transactivation of the CRE promotor, resulting in reduced expression of downstream CREB-
regulated genes, including two well-characterized survival mediators, Bcl2 and BDNF. CRE 
transcriptional repression is accompanied by altered subcellular localization of CREB/pCREB, 
with increases of this important transcription factor being seen in the cytoplasm, and a 
corresponding decrease seen in nuclei.  Similar alterations are observed in dopaminergic neurons 
of primary midbrain cultures and human parkinsonian post-mortem tissue, as both show 
abnormal expressions pattern for CREB.  
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We also have determined that 6-OHDA-induced repression of CRE could be reversed 
with cAMP treatment, an effect that was associated with significant protection from toxicity.  
Interestingly, since this repression could be reversed by delayed cAMP treatment several hours 
after initiation of 6-OHDA induced injury, and this delayed cAMP administration could also 
confer protection even when applied up to four hours after injury, it is likely that these effects are 
occurring early in the injury process, prior to cell death commitment and lysis.  These data 
indicate that inhibition of the CREB signaling pathway plays a direct role in oxidative stress–
induced toxicity in neuronal cells. Since a similar disruption in CREB was seen in primary 
neurons as well as in human brain tissue, it is likely that the effects seen in our cell lines are 
relevant to neuronal cell death processes that occur in neurodegenerative diseases.  
5.2 CREB DYSFUNCTION IS DUE TO SUB-CELLULAR DIVERSION, NOT 
INHIBITION OF PHOSPHORYLATION.  
While previously published papers have implicated disruptions in CREB signaling in neuronal 
death, these current studies provide a novel mechanism of CREB disruption, with potential 
relevance to Parkinsonian neurodegeneration.  For example, in other model systems, it has been 
shown that oxidative stressors can disrupt CREB function by interfering with CREB 
phosphorylation and/or by reducing CRE binding activity (Ito et al. 1999) (See and Loeffler 
2001).  More specifically, exposure of neuronal cells to H2O2 significantly decreased CREB 
phosphorylation, and if this phosphorylation is restored, neurons are protected from oxidant-
induced death (See and Loeffler 2001).  While our own studies similarly show that a disruption 
in CREB pathway contributes to neuronal death, the mechanism by which CREB function is 
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altered appears to be different.  Their observation of decreased CREB phosphorylation was not 
seen in our studies, as we have determined that CREB phosphorylation is increased in response 
to 6-OHDA, with most of the CREB immunoreactivity retained in the cytoplasm (Figures 15, 18, 
22, 15).  The accumulation of CREB and pCREB in the cytoplasmic compartment indicates that 
6-OHDA treatment may interfere with nuclear translocation of phosphorylated CREB.  Whether 
nuclear import of CREB (after its synthesis in the cytoplasm) is being inhibited or nuclear export 
is being activated is still unclear, but each is an exciting possibility that warrants further study. 
One possible mechanism responsible for inhibition of nuclear translocation is 
modification of the nuclear localization signal within CREB (located within the basic leucine-
zipper domain(Waeber and Habener 1991).  While there are numerous studies on the nuclear 
import of transcription factors from the cytoplasm through NLS (Kallio et al. 1998) and (Fenarli 
et al. 2004),  relatively little attention has been paid to the export of different transcription factors 
from the nucleus, and even less so regarding CREB.  However, one study that did examine 
CREB subcellular localization determined that loss of CREB can be induced in smooth muscle 
cells (SMC’s) by chronic exposure to hypoxia or platelet-derived growth factor BB, and 
treatment with the nuclear export inhibitor leptomycin B prevented this depletion of nuclear 
SMC CREB (Garat et al. 2006).  This work indicates active export of CREB as a mechanism for 
transcriptional control.   It would be worthwhile to examine the effects of the nuclear export 
inhibitors in our model system, to further substantiate the hypothesis that active nuclear export is 
contributing to cytoplasmic CREB accumulation. 
Additionally, it is also possible that the accumulation of CREB in the cytoplasm may 
further suggest the possiblity that dephosphorylation of pCREB is interrupted in response to 
oxidants, or that degradative systems are disrupted (Zhu et al. 2003) (Keller et al. 2004) (Chu 
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2006).   Both of these options would contribute to the cytoplasmic accumulation of signaling 
proteins within cells.  Regardless of the contribution, these results suggest that subcellular 
diversion of CREB proteins, rather than inhibition of phosphorylation, is responsible for the loss 
of neuroprotective CRE transcriptional activity.   
5.2.1 Nuclear/cytoplasmic trafficking of transciption factors.  
The regulation of nuclear/cytoplasmic trafficking of transcription factors is a central mechanism 
to controlling gene expression. It is widely believed that nuclear import and export proceed 
through nuclear pore complexes and can occur by a variety of distinct mechanisms  (Reviewed in 
(Nakielny and Dreyfuss 1999).  For example, a major nuclear-cytoplasmic trafficking pathway is 
believed to consist of cytosolic receptor molecules of the importin superfamily, which recognize 
and dock the NLS-containing proteins at the nuclear pore.  The affinity of the importin-targeting 
sequence interaction is a crucial factor in determining the efficiency of translocation, and can be 
influenced by phosphorylation. Phosphorylation can result in the masking of targeting sequence 
or the increased affinity of the interaction with importins  (Jans et al. 2000).  For example, 
phosphorylation of the yeast transcription factor, PHO4, blocks its interaction with nuclear 
import proteins, keeping it retained in the cytoplasm (O'Neill et al. 1996). Subsequent 
dephosphorylation allows binding with its import receptor, permitting nuclear translocation, 
DNA binding and initiation of transcription to occur.  In another example, phosphorylation of the 
cytoplasmic retention factor, kB, disrupts its interaction with the transcription factor NFkB, 
allowing the NLS of NFkB to be recognized by import receptors (reviewed in (Nakielny and 
Dreyfuss 1999).  Although phosphorylation seems to be the predominant mechanism in 
controlling transciption, it might not be the only posttranslational modification involved. For 
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example, methylation of arginine residues has also been found to have an effect on the export of 
some yeast proteins (see review above). 
It is possible that phosphorylation or oxidation of the NLS in CREB may be responsible 
for the altered subcellular localization described in our studies.  While CREB is generally 
thought to be constitutively expressed in the nucleus, this widely held belief is beginning to be 
challenged.  For example, studies have shown that CREB can be localized to the neuronal 
dendrites (Crino et al. 1998) as well as other cellular compartments including the cytoplasm 
(Kuramoto et al. 2005)  It is possible that under some circumstances, cell stimulation could 
prompt CREB to translocate into or out of the nucleus.  Alterations in nuclear translocation in 
neurons during injury may represent a previously unexplored control mechanism, allowing the 
cell an additional level of control over CREB signaling in neuronal cells, or may represent an 
abnormal response to oxidant exposure.  Further examination of CREB NLS is necessary. 
5.2.2 Nuclear translocation of CREB.   
Interestingly, it has been shown in other cell types that inhibitors of nuclear import can elicit 
altered subcellular localization patterns of CREB as well as disruptions in CREB-mediated 
transcriptional responses.  For example, in smooth muscle cells, Stevenson et al  (Stevenson et 
al. 2001) described a new and potentially important mechanism for the differentiation of CREB 
signals.  Blockage of nuclear transport led to the accumulation of phosphorylated CREB in the 
cytoplasm and reduced pCREB activity.  However, this reduced activity was restricted to 
specific stimuli.   For example, CRE transcriptional responses to platelet derived growth factor 
receptor (PDGF) or membrane depolarization were inhibited when nuclear import was blocked, 
which contributed to cytoplasmic accumulation of pCREB.  But inhibition of nuclear import had 
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no effect on the subcellular distribution of pCREB or CRE-mediated transcription when muscle 
cells were stimulated by forskolin (Stevenson et al. 2001). Interestingly, PDGF signals to CREB 
via the MAP Kinase pathway, while forskolin activates the cAMP/PKA pathway.  Because the 
catalytic subunit of PKA is small and can passively diffuse into the nucleus through nuclear 
pores, active nuclear import is not required.  However, both PDGF and depolarization stimuli 
regulate CREB phosphorylation via large cytoplasmic kinases such as ERK and RSK, which 
need to translocate into the nucleus to take effect, and therefore would be sensitive to disruption 
in nuclear trafficking.  Cellular regulation of nuclear import adds another level of control to 
CREB signaling, and may represent an additional mechanism that mediates specificity.  
Additionally, this regulation may become altered, or abnormally activated in response to oxidant 
treatment. 
5.2.3 Summary. 
Taken together, the current and previously published data suggest that 6-OHDA treatment results 
in impaired nuclear import of pCREB, which accumulates in the cytoplasm. The addition of 
cAMP is able to bypass the signaling blockage through mechanisms that likely involve PKA, 
resulting in restoration of neuroprotective CRE transcriptional responses (Figure 11). Indeed, our 
H89 experiments that were performed implicate involvement of PKA in cAMP effects in our 
system (Figure 13), strengthening this hypothesis. Interestingly, we also determined that 
treatment of neuronal cells with MEK inhibitors, which ultimately inhibit the activation of ERK, 
caused a repression in basal levels of CRE activation (Figure 14).  Since the PKA inhibitor H89 
did not affect basal CRE activity at all,  it is likely the basal levels of CREB activity in these 
neuronal cells in culture work predominantly through the MAP Kinase pathway, and not through 
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PKA.  6-OHDA caused inhibition of this ERK-CREB pathway, which resulted in cell death, 
while stimulation of the alternate cAMP/PKA pathway conferred protection. Since a disruption 
of nuclear translocation would affect only the MAP Kinase pathway, leaving PKA untouched 
and free to diffuse and activate any nuclear CREB, these results strengthen our hypothesis that 
inhibition of CREB signaling occurs through alterations in nuclear/cytoplasmic trafficking.  It is 
necessary and important to extend these studies by examining any alterations in the CREB 
nuclear localization signal (phosphorylation, methylation, etc) as well as examining the effects of 
inhibitors of nuclear import/export to determine the potential mechanism responsible for altered 
CREB trafficking in our model system. 
5.3 A COMMON DEFICIT IN NUCLEAR TRANSLOCATION IN 
NEURODEGENERATION 
5.3.1 ERK signaling is disrupted in neuronal death.  
Previous data from our laboratory and others demonstrated that spatial and temporal alterations 
in the ERK signaling pathway, a well-known upstream CREB activator, may be contributing to 
neurodegenerative disease pathologies.  For example, pERK is aberrantly expressed in the brains 
of patients with Alzheimer’s Disease (Zhu et al. 2002), and is increased in the vulnerable 
penumbra in the brains of patients following acute ischemic stroke (Slevin et al. 2000).  pERK 
has also been implicated in Parkinson’s pathogenesis and 6-OHDA-mediated neuronal death  
(Zhu et al. 2002) (Zhu et al. 2003), where it was demonstrated that granular cytoplasmic 
accumulations of  pERK are present in both a 6-OHDA treated neuronal cell lines as well as in 
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degenerating neurons of human Parkinson's disease brain (Zhu et al. 2002) (Zhu et al. 2003). In 
human PD tissue, the cytoplasmic aggregates were localized to the substantia nigra, and were 
largely absent in control cases.  Interestingly, examination of pre-clinical cases indicate that 
these pERK alterations may be occurring relatively early in the disease process, a finding that 
may have important clinical implications, and correlates well with our current findings. It was 
also demonstrated that neuroprotective anti-oxidant treatments blocked cytoplasmic 
accumulation in the neuronal cell line (Zhu et al. 2002), supporting a role for oxidants eliciting 
neurotoxic patterns of ERK activation.  
In these human tissue studies, when the subcellular localization of phospho-ERK 
immunoreactive granules was examined using double label confocal microscopy and immuno-
electron microscopy, it was revealed that p-ERK labeling was targeted to mitochondria, and 
heavily labeled mitochondria were observed within autophagosomes of damaged neurons (Zhu et 
al. 2003).  This suggests that a potential interaction between dysfunctional mitochondria, 
autophagy, and ERK signaling pathways exists in neuronal pathologies.  Additonally, since 
separate, independent studies have suggested the possibility that CREB can accumulate in 
mitochondria under pathological conditions (Cammarota et al. 1999), (Lee et al. 2005), it is 
possible that the increased expression of pCREB in the cytoplasm shown in our studies in this report 
similarly represents an increase in mitochondrial accumulation. The extraction protocol used in these 
studies to isolate nuclear and cytoplasmic fractions (NePER, Pierce Biotechnology) concentrates 
mitochondria in the cytoplasmic/cytosolic fraction.  This fraction could be further processed for 
mitochondrial isolation, with subsequent separation of mitochondria by centrifugation and percoll 
gradient  (See (Zippin et al. 2003) for technique).   This was not attempted in these studies.  However, a 
preliminary examination using immunofluorescence studies of 6-OHDA-treated B65 cells showed that 
pCREB did not co-localize with mitochondrial markers (data not shown).  Additional studies are needed 
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to determine if cytoplasmic pCREB, like pERK, is being targeted to mitochondria, which may be 
subsequently targeted to lysosomes. While these preliminary results in the one cell line indicate that 
pCREB is not accumulating in mitochondria, further clarification of this issue should be pursued 
in SH-SY5Y cells to more concretely define subcellular localization patterns.  
Taken together, these data lend further support to our hypothesis that diversion of 
important signaling components may directly contribute to cell death.   However, while 
abnormal activation of ERK seems to be a common theme in the neuronal death process, its 
exact mechanism remains unknown.  Since studies have suggested that ERK may be 
accumulating in mitochondria, some of which are damaged and being autophagocytosed (Zhu et 
al. 2003), it is unclear to date whether CREB shares a similar fate.  Additional studies to 
determine precise cytoplasmic location of CREB are needed. 
5.3.2 RSK is disrupted in neuronal death. 
As previously described, one important target of pERK is the ribosomal S6 kinase (RSK), which, 
once activated, can phosphorylate targets in both the cytoplasm and nucleus.  Further 
examination of this ERK-RSK-CREB pathway by our laboratory showed that phosphorylated-
RSK is also increased within the cytoplasm in neuronal cells in response to 6-OHDA, in an 
aggregated pattern similar to the abnormal ERK distribution induced by 6-OHDA (Zhu et al. 
2002).  Increases in cytoplasmic pRSK were similarly seen in the substantia nigra neurons in PD 
brain tissue, again in the aggregated cytoplasmic pattern.  Interestingly, this effect was specific 
for RSK, as a separate ERK target, the transcription factor Elk-1, was not altered in substantia 
nigra neurons (Zhu et al. 2002). Since RSK typically translocates to the nucleus after stimulation 
by ERK where it can phosphorylate CREB, these results further suggest that nuclear/cytoplasmic 
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trafficking is altered in neuronal death pathways.  With RSK unable to translocate to the nucleus, 
alterations in CREB activation would be not be unexpected.  Additionally, with p-RSK 
accumulating in the cytoplasm, it raises the possibility that any accumulated cytoplasmic CREB 
might, in theory, be phosphorylated locally by pRSK.   However, while cytoplasmic pERK has 
been determined to be active in this model, the enzymatic activity of pRSK was not tested in 
these studies.  Further examination of this important kinase is warranted. 
5.3.3 Evidence of disruption in other important signaling proteins. 
Additional evidence of cytoplasmic diversion of important nuclear signaling proteins has been 
described in other models of neuronal death.  For example, aberrant cellular localization of E2F1 
and pRb, two key regulators of the cell cycle, have been described in  damaged neurons in the 
simian immunodeficiency virus encephalitis (SIVE) model. Compared to non-infected and non-
encephalitic controls, expression of both of these nuclear factors was abnormally increased in the 
cytoplasm of neurons (Jordan-Sciutto et al. 2000).  Additionally, in Parkinson’s Disease brain 
tissue, immunoreactivity for pRB was also shown to be abnormally increased in neuronal 
cytoplasm of the substantia nigra neurons (Jordan-Sciutto et al. 2003).  In fact, pRB exhibited a 
staining pattern that was strikingly similar to our observed results with pCREB.  These combined 
results indicate that cytoplasmic diversion of important signaling components is likely a common 
factor in damaged and dying neurons in human disease. Whether this result is due to a disruption 
in nuclear import, an abnormal activation of nuclear export, and/or alterations in 
dephosphorylation mechanisms still remains unclear, and awaits further study. 
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5.3.4 Summary 
The current sub-cellular fractionation and immunofluorescence data showing accumulation of 
pCREB in the cytoplasm and loss of CRE-mediated transcriptional activity in 6-OHDA treated 
cells along with the abnormal expression patterns of ERK and RSK suggest the possibility of a 
common deficit in nuclear translocation. Since the phosphorylated forms of ERK, RSK, and 
CREB are all increased in granular or clumped cytoplasmic distribution in degenerating human 
substantia nigra neurons, it is likely that altered nuclear trafficking may underlie impaired 
survival signaling in human neurodegenerative diseases.  Additionally, as the Parkinson's disease 
related protein α-synuclein is also known to accumulate in the cytoplasm of affected neurons, 
and shares homology with 14-3-3 like properties (Ostrerova et al. 1999),  the potential 
involvement of α-synuclein aggregation in altering the distribution of these signaling proteins 
deserve further study. 
5.4 DOWNSTREAM CREB-MEDIATED GENES ARE DISRUPTED IN RESPONSE 
TO 6-OHDA. 
A role for altered expression of BDNF and Bcl2 in parkinsonian neurodegeneration has been 
suggested by several studies of diseased human tissues and model systems.  For example, BDNF 
expression levels are decreased in the substantia nigra of Parkinson's disease patients (Mogi et al. 
1999; Howells et al. 2000), and BDNF treatment reverses the motor deficits induced by 6-OHDA 
in vivo (Klein et al. 1999).  Additionally, over-expression of Bcl-2 in rat brain prior to 6-OHDA 
administration results in increased survival of neurons within substantia nigra (Yamada et al. 
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1999; Natsume et al. 2001), and Bcl-2 family members can inhibit 6-OHDA-induced death in 
SH-SY5Y cells (Jordan et al. 2004). A further study reported that oxidative stress causes a down-
regulation of the Bcl2 promoter, resulting in a decrease in Bcl2 protein as well as mRNA levels 
(Pugazhenthi et al. 2003) It is clear that proper expression of both of these survival mediators 
plays a critical role in neuronal survival.  
5.4.1 Functional relevance of decreased BDNF and Bcl2 message. 
Our findings that BDNF and Bcl2 mRNA levels are decreased with 6-OHDA treatment  (Figure 
10) indicate a loss of CRE-controlled gene expression, and provide a functional consequence for 
decreased CRE transcription. These and previous data support the concept that impaired survival 
signaling contributes to dopaminergic cell death as well as parkinsonian pathogenesis. However, 
whether the loss of either of these two gene products has a direct role in neuronal death 
mechanisms in our model is not completely clear, and requires further investigation.  The fact 
that stimulation of B65 cells with BDNF alone was not able to protect them from 6-OHDA-
induced toxicity  (Figure 9), despite the fact that these cells express TrkB receptors and respond 
to BDNF treatment by increasing CREB activity (data not shown), may indicate that restoration 
of BDNF  alone is not enough to compensate for all of the 6-OHDA induced changes.  Since 
BDNF signals through neurotrophin receptors that typically stimulate the ERK pathway, if 
nuclear trafficking is disrupted in response to 6-OHDA as hypothesized, then one would predict 
that BDNF would not be able to successfully activate survival mechanisms. In our model, the 
ERK pathway is disrupted in such a way that important components are sequestered in the 
cytoplasm and unable to enter the nucleus, and would result in disrupted BDNF signaling. In 
 88 
short, BDNF would not be able to bypass the 6-OHDA-induced nuclear translocation blockade 
of the ERK-RSK-CREB pathway.   
As 6-OHDA also represses the CRE-related gene Bcl-2 and co-treatment with cAMP 
restores Bcl-2 mRNA, one would predict reciprocal effects on caspase 3 activity. Indeed, we 
found that 6-OHDA elicits increased caspase 3 activity, and co-treatment with cAMP 
significantly attenuates this response in SH-SY5Y cells (Figure 23) which undergo well-
described apoptosis in response to several stimuli (Yuste et al. 2002; Kalivendi et al. 2003; Lee 
et al. 2005).  In contrast, B65 cells appear to undergo an alternative form of ERK dependent cell 
death that lacks classic apoptotic features (CT Chu, unpublished data), and accordingly, caspase 
3 was not activated in response to 6-OHDA. However, it is possible that at the time point 
examined (3 hours) apoptosis has simply not yet begun in B65 cells, and apoptotic changes occur 
after longer exposures to toxin. Regardless, the similarities between the two cell lines in terms of 
early transcriptional alterations further suggest that CREB-related changes are upstream to and 
independent of the specific execution mechanism. Since Bcl-2 can protect against both apoptotic 
and alternative death pathways (Yuan et al. 2003) and CREB regulated transcription is 
neuroprotective in ischemic and excitotoxic neuronal death (Mabuchi et al. 2001), these results 
along with our delayed protection experiments (Figure 8) indicate that the CREB alterations are 
likely involved in early cell fate decisions in injured neurons prior to cell death commitment.  A 
loss of both BDNF and Bcl2 mRNA is occurring in both cell lines in response to 6-OHDA, and 
impaired survival signaling is likely contributing to dopaminergic cell death. 
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5.4.2 CREB controlled genes are not upregulated. 
Previous studies of transcriptional responses to 6-OHDA focused upon upregulation of genes 
potentially involved in death pathways (Holtz and O'Malley 2003; Ryu et al. 2005). Both the 
unfolded protein/endoplasmic reticulum stress response and c-jun induction were implicated. Of 
interest is the data indicating that c-jun/ATF/CREB heterodimerization may determine whether 
increased protein-CRE binding activity results in suppression rather than induction of CRE-
transcription (Zhang et al. 2004). While genes whose expression was downregulated by 6-OHDA 
were not analyzed in these reports, the fact that CRE-regulated genes, such as Bcl-2, were not 
upregulated along with other genes involved in bioenergetics and death regulation are consistent 
with our results showing decreased CRE-regulated transcription in 6-OHDA treated cells. 
5.4.3 Summary 
In summary, it is clear that the downstream CREB-mediated gene products, BDNF and Bcl2, are 
disrupted in response to 6-OHDA.  Since disruptions in both of these survival mediators have 
been implicated in neuronal death, it is possible that the loss of one or both of them contribute to 
death in our model system.  Further study examining the impact of decreased BDNF and Bcl2 
expression in response to oxidative toxins is warranted. 
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5.5 PROTECTION OF NEURONAL CELLS FROM OXIDATIVE STRESS  
5.5.1 Protection from 6-OHDA toxicity may require unidentified cofactors  
While our data indicate that cytoplasmic diversion/retention of P-CREB contributes in part to 6-
OHDA repression of CRE transcription, cAMP may act through additional mechanisms other 
than simple reversal of 6-OHDA induced decreases in nuclear CRE binding activity in order to 
induce protection. It is not clear why cAMP-induced restoration of nuclear pCREB observed in 
B65 and SY5Y cells by western blot and immunoflourescence (Figures 15, 22) is not reflected 
by increased CRE probe binding in EMSA (Figure 12).  Although it is accepted that cAMP 
enhances the transactivation potential of CREB, this is often not correlated with increased DNA 
binding affinity (Mayr and Montminy 2001).  As discussed earlier, basal levels of CRE site 
occupancy vary from promoter to promoter, as for example, CREB occupancy of CRE seems to 
be constitutive for promoters such as Cyclin-D and cfos but CREB binding to CRE in the CRF 
promoter is heavily stimulated by cAMP agonists (Sibinga et al. 1999) (Dey et al. 1991).  The 
fact that the altered regulation of CRE transcription observed in our system seems to show a 
greater magnitude than the alterations in nuclear pCREB levels detected by western blot or 
EMSA suggests that a heterogeneity in the protein composition of the complexes bound to CRE 
may be responsible.   
Additionally, it is widely believed that differences in CREB activity in response to various 
stimuli can be attributed to the differential binding of specific cofactors, as recruitment of 
various complexes to the different gene promoters allow a particular CREB target gene to 
respond to one signal but not the other.  For example, phosphorylation of CREB alone is 
typically not sufficient for growth factor stimulation of CRE gene expression, as additional 
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promoter-bound factors are necessary.   In our model system, it is possible that cAMP increases 
the transcriptional efficiency of bound CREB through increased binding of co-activators or 
perhaps through changes of the stoichiometry of CREB heterodimers to favor transcription. One 
possible candidate is CREB binding protein (CBP), as sequestration of CBP is believed to be a 
pathogenic mechanism on other systems  (Nucifora et al. 2001).  However, our immunoblots of 
CBP show no differences in nuclear levels of this protein, and no alteration in cytoplasmic 
fractions (Figure 17).  It would be worthy to examine other known CREB co-activators and 
repressors in the future, to determine specific alterations in CRE binding components.  
Additionally, since CREB can be phosphorylated as a consequence of calcium signaling, through 
activation of ERK regulated kinases, or by cAMP-activated protein kinase A (PKA), it is also 
possible that the integration of these pathways may be necessary for full stimulation of CREB-
dependent transcription. 
5.5.2 A role for antioxidants in 6-OHDA toxicity. 
While 6-OHDA toxicity can be ameliorated by a spectrum of antioxidants (Kulich and Chu 
2001; Zhu et al. 2002; Kulich and Chu 2003), the roles of specific oxidative mediators and their 
compartmentalization are much less clear. Previous studies of the ERK signaling pathway 
indicate that LD50 doses of hydrogen peroxide do not have the same signaling effects as LD50 
doses of 6-OHDA (Kulich and Chu 2001). Additional studies further suggest that while 
antioxidants may inhibit 6-OHDA-mediated CRE repression, hydrogen peroxide does not repress 
CRE transcription in B65 or SH-SY5Y cells (Figure 26). Moreover, hydrogen peroxide 
increases, rather than decreases CREB DNA binding in primary cortical neurons (J Caltagorone 
& R Bowser, unpublished data) which is in contrast to our observations with 6-OHDA. Thus, 
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while antioxidants inhibit 6-OHDA-induced toxicity and signaling alterations in vitro (Kulich 
and Chu 2001; Zhu et al. 2002; Kulich and Chu 2003), and in vivo (Callio et al. 2005), the 
signaling alterations likely result from specific mechanisms relating to the nature of the toxin 
itself, or to specific interactions within dopaminergic cells.  
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Figure 26.   H2O2 does not repress the CRE promoter. 
 
B65 cells were transfected with CRE-luciferase plasmid, and treated with media (UT), 
cAMP (500uM), 6-OHDA (500uM) or H2O2 (500mM) for 3 hours.  Lysates were collected 
and analyzed for luciferase activity as described in Methods.  Data is expressed as fold 
induction over untreated control.  6-OHDA causes a repression of CRE, but H2O2 does not. 
 
Preliminary experiments done in our lab examining the effect of antioxidants on CRE 
activity and CREB localization provided some interesting results.  For example, pre-treatment of 
neuronal cells with antioxidants (Catalase and TBAP) prior to 6-OHDA exposure resulted in 
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decreased CRE repression (Figure 27 below).  Additionally, antioxidant treatment also decreased 
the 6-OHDA-induced cytoplasmic accumulation of pCREB (data not shown). These results are 
preliminary and need to be repeated, but suggest that antioxidants can partially alleviate CRE 
repression and cytoplasmic buildup of CREB, effects that may play a role in antioxidant-induced 
protection from 6-OHDA toxicity. 
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Figure 27.  Antioxidants affect 6-OHDA-mediated effects in B65 cells. 
 
Cells were transfected with CRE luciferase and treated with either media, catalase (30 
U/ml), or MnTBAP (100 uM) 10 minutes prior to treatment with either vehicle or 500 uM 
6-OHDA. Luciferase activity was normalized to cells treated with media alone (untreated). 
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5.5.3 6-OHDA toxicity is specific to dopaminergic neurons. 
Similar observations in two catecholaminergic cell lines and in primary dopaminergic neurons 
indicate that altered CREB regulation is a common response of catecholaminergic cells to this 
toxin. As 6-OHDA is targeted to cells that express the high affinity dopamine transporter, it can 
be difficult to separate cell type specific effects from toxin specific effects. Interestingly, while 
loss of nuclear pCREB is observed in 6-OHDA injured TH+ neurons in primary culture, the non-
TH neurons retain robust nuclear pCREB expression (Fig. 24D). These non-TH neurons are 
largely spared during Parkinson’s Disease.  This supports the hypothesis that failure to 
successfully upregulate neuroprotective CREB dependent transcription may underlie lethal 
effects of 6-OHDA in catecholaminergic cells. 
5.5.4 A window for protection  
Pulse-chase experiments indicated that 6-OHDA treated B65 cells are committed to die in a 
delayed fashion following transient exposures to 6-OHDA (Kulich and Chu 2001). The current 
data indicate that there is no significant LDH release until 8 h after 6-OHDA exposure (Figure 
4C).  It is interesting to note that cAMP is able to confer significant protection even when 
applied 4 h after injury, a time occurring after commitment to death (in the absence of protective 
interventions) and prior to initiation of cell lysis. In contrast, antioxidants can prevent cell death 
only when added within the first 15-60 min of injury (Kulich & Chu, unpublished data). This 
indicates that downstream signaling alterations induced by oxidative neurotoxins may prove 
amenable to therapeutic manipulation after the window of time when antioxidants are able to 
prevent injury. 
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5.6  SUMMARY AND CONCLUSIONS 
5.6.1 Clinical Relevance. 
These results indicate that a disruption of the CRE signaling pathway is involved in 6-OHDA-
mediated neuronal death. As CREB dysfunction has also been implicated in many human 
pathologies, it is likely that these results may have important clinical implications.  Adding 
strength to this concept is the recent data showing CREB imvolvement in levodopa- (L-dopa) 
induced improvement in motor responses in Parkinson’s Disease models (Oh et al. 2003).  In PD 
patients, treatment with the dopamine precurser, L-dopa, usually confers significant clinical 
benefit, providing drastic improvement in patients’ motor function.   Since dopamine receptors 
(the D1 subtype) stimulate PKA-mediated phosphorylation of CREB (Surmeier et al. 1995), it 
was hypothesized that L-dopa treatment stimulates striatal CREB phosphorylation in the brain 
and contributes to the maintenance of motor response changes.  Indeed, a study by Oh et al 
(2003) using 6-OHDA lesioned rats, showed that treatment with L-dopa resulted in a dramatic 
increase in Ser-133 phosphorylated CREB in the striatum and concurrently improved motor 
function.  In addition, the time course of alterations in CREB phosphorylation correlated with the 
changes in motor function after L-dopa treatment was stopped, and inhibitors of PKA resulted in 
decreased striatal pCREB as well as a loss of motor improvement.  These results further support 
the idea that disruption in phosphorylated CREB is contributing to the progression of PD 
symptoms, and that stimulation of CREB, via PKA, may improve neuronal function and 
survival.  Since our current results show sequestration of pCREB in the cytoplasm of affected 
neurons in PD brain tissue, it is possible that L-dopa treatment causes stimulation of any 
remaining nuclear CREB (via the dissociation and diffusion of PKA) and can buy neurons more 
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time.  In the future, additional therapies designed to target PKA and/or CREB directly may offer 
further benefit to Parkinson’s patients. 
Sequestration of CRE activator proteins (other than CREB itself) has also been suggested 
to play a causal role in the progression of additional neurodegenerative diseases, such as 
Huntington’s disease (Nucifora et al. 2001).  In these studies, intra-nuclear aggregation of CREB 
binding protein (CBP) occurs, preventing access to its CREB target and resulting in decreased 
gene transcription and subsequent disease pathology. Additionally, persistent ERK activation in 
liver cells results in increased binding of CBP to RSK within the nucleus, which resulted in 
decreased phosphorylation of CREB and attenuation of CRE-mediated gene expression (Wang et 
al. 2003), which was associated with cell growth inhibition. While these differ from our study in 
showing nuclear sequestration and reduced levels of CREB phosphorylation, impaired ability to 
mount protective CRE transcriptional responses may represent a common mechanism in cellular 
damage and in neurodegenerative diseases.  CREB activators, as well as CREB targets may 
potentially offer new avenues of therapy for treatments of neurodegenerative diseases. 
5.6.2 Conclusions 
In conclusion, this data taken together with previously published results suggest that 6-OHDA 
treatment results in impaired nuclear import of ERK, RSK and CREB, all of which accumulate 
in the cytoplasm.  The addition of cAMP, likely working through PKA, is able to bypass the 
signaling blockage, resulting in restoration of neuroprotective CRE transcriptional activity  
(Figure 28). Given the increasing reports of signaling proteins and transcription factors 
accumulating in the cytoplasm of degenerating neurons, strategies to bypass potential 
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translocation deficits may aid in the development of new strategies for neurodegenerative disease 
treatment. 
This cytoplasmic sequestration of signaling proteins or transcription factors may 
represent a novel mechanism contributing to failed compensation during oxidative neuronal 
injuries. The discovery of impaired signaling mechanisms in injury models indicates that trophic 
factor supplementation therapies may need to consider strategies for bypassing or reversing 
potential downstream blockages elicited by disease or age-associated oxidative stressors. While 
the specific mechanisms leading to impairment of protective CRE transactivation in the 6-OHDA 
model differs from those described previously for other oxidative or neurodegeneration models, 
the overall effect of disruption in CREB function is a consistent theme.  The ability of cAMP to 
mobilize potentially active pools of pCREB and/or to provide compensatory stimulation of 
nuclear CREB to override the deficit in CRE-dependent transcription may prove beneficial to 
neurodegenerative therapies. 
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Figure 28.  Possible disruption in the CREB Pathway in response to 6-OHDA. 
 
In our model, 6-OHDA exposure results in cytoplasmic sequestration of ERK, RSK and 
CREB, which is accompanied by the repression of CRE-mediated transcription (X) and 
subsequent decreases in downstream BDNF and Bcl2 gene expression (∅).  It is possible 
that a blockage of nuclear translocation (red arrow) is occurring in response to 6-OHDA.  
Administration of cAMP bypasses this blockade (green arrows) and restores CRE 
transcriptional activity, and conferring significant protection if administered prior to the 
initiation of cell lysis.  Given the increasing reports of signaling proteins and transcription 
factors accumulating in the cytoplasm of degenerating neurons, strategies to bypass 
potential translocation deficits may prove promising. 
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